Cationic Palladium(II)-Catalyzed Synthesis of Substituted Pyridines from α,β-Unsaturated Oxime Ethers

Supporting Information

Takahiro Yamada, Yoshimitsu Hashimoto, Kosaku Tanaka, III, Nobuyoshi Morita and Osamu Tamura*

Showa Pharmaceutical University, 3-3165 Higashi-Tamagawagakuen, Machida, Tokyo 194-8543, Japan

E-mail: tamura@ac.shoyaku.ac.jp

Table of contents

General methods	S2
Pyridine ligand optimization	S2
Oxime ether optimization	S3
Reaction optimization	S4
General procedure for substituted pyridine synthesis	
Investigation of the amount of catalysts and oxidant	S5
Control experiments with specific substrates and conditions	S6
Preparation of ligands	S 11
Preparation of substrates	S12
Palladium(II)-catalyzed substituted pyridine synthesis	S20
ωB97X-D/6-311+G(d,p) Calculated cartesian coordinates	S36
Crystallographic description of 2-benzylidenecyclopentenone oxime ether (18)	S39
References	S39
NMR data of new compounds	S40

General methods

¹H and ¹³C NMR spectra were recorded with BRUKER AV300M spectrometer at room temperature, with tetramethylsilane ($\delta = 0$) as an internal standard (CDCl₃ solution). Chemical shifts were expressed in ppm, and coupling constants (*J*) in Hz. Infrared (IR) spectra were recorded with a Shimadzu IRSpirit. Mass spectra were recorded on JEOL JMS-700 and JMS-T100LP spectrometers. Melting points were determined by using a Yanaco melting point apparatus MP-S3. Merck silica gel 60 F254 and Wako NH₂ silica gel 60 F254 were used for thin layer chromatography (TLC). Merck silica gel 60 (1.09385) and Kanto Chemical silica gel 60 (spherical) NH₂ were used for column chromatography, and the all pyridine products were purified by flash column chromatography on NH₂ silica gel as previously reported.¹ All computations were carried out with the Gaussian 09 series of programs.² All compounds were calculated with ω B97X-D/6-311+G(d,p), and an ultrafine grid was used for geometry optimization.

Pyridine ligand optimization



General procedure for pyridine ligand optimization using α,β -unsaturated oxime ether 1a¹ To a solution of α,β -unsaturated oxime 1a (0.2 mmol, 1.0 eq.), methyl acrylate (2a, 0.6 mmol, 3.0 eq.), AgTFA (0.5 mmol, 2.5 eq.), and ligand (0.06 mmol, 30 mol%) in dioxane (2.0 mL) was added Pd(OAc)₂ (0.02 mmol, 10 mol%). The reaction mixture was stirred at 90 °C (silicone oil bath) for 24 h, then diluted with AcOEt and filtered through a Celite[®] pad (rinsed with AcOEt). The filtrate was concentrated in *vacuo*, and the crude product was purified by flash column chromatography on NH₂ silica gel (hexane : AcOEt = 3 : 1) to afford the desired pyridine **3** as a white solid.

Oxime ether optimization



General procedure for oxime ether optimization¹

To a solution of α , β -unsaturated oxime **1** (0.2 mmol, 1.0 eq.), methyl acrylate (**2a**, 0.6 mmol, 3.0 eq.), AgTFA (0.5 mmol, 2.5 eq.), and **L3** (0.06 mmol, 30 mol%) in dioxane (2.0 mL) was added Pd(OAc)₂ (0.02 mmol, 10 mol%). The reaction mixture was stirred at 90 °C (silicone oil bath) for 24 h, then diluted with AcOEt and filtered through a Celite[®] pad (rinsed with AcOEt). The filtrate was concentrated in *vacuo*, and the crude product was purified by flash column chromatography on NH₂ silica gel (hexane : AcOEt = 3 : 1) to afford the desired pyridine **3**.

Reaction with oxime 1d



To a solution of α , β -unsaturated oxime **1d** (50 mg, 0.2 mmol, 1.0 eq.), methyl acrylate (**2a**, 0.6 mmol, 3.0 eq.), AgTFA (0.5 mmol, 2.5 eq.), and **L3** (0.06 mmol, 30 mol%) in dioxane (2.0 mL) was added Pd(OAc)₂ (0.02 mmol, 10 mol%). The reaction mixture was stirred at 90 °C (silicone oil bath) for 24 h, then diluted with AcOEt and filtered through a Celite[®] pad (rinsed with AcOEt). The filtrate was concentrated in *vacuo*, and the crude product was purified by flash column chromatography on NH₂ silica gel (hexane : AcOEt = 3 : 1) to afford isoxazole **5**³ (19.8 mg, 39% yield) as a white solid. ¹H NMR (CDCl₃, 300 MHz) δ 7.83 (dd, 2H, *J* = 10.4, 2.4 Hz), 7.16–7.57 (m, 10H), 6.77 (s, 1H). Spectra data of obtained product was in good agreement with previously reported literature.^{3b}

Reaction optimization

To a solution of α , β -unsaturated oxime **1** (0.2 mmol, 1.0 eq.), methyl acrylate (**2a**, 0.6 mmol, 3.0 eq.), oxidant (x equiv), and ligand (0.06 mmol, 30 mol%) in dioxane (2.0 mL) was added Pd cat. (0.02 mmol, 10 mol%). The reaction mixture was stirred at 90 °C (silicone oil bath) for 24 h, then diluted with AcOEt and filtered through a Celite[®] pad (rinsed with AcOEt). The filtrate was concentrated in *vacuo*, and the crude product was purified by flash column chromatography on NH₂ silica gel (hexane : AcOEt = 3 : 1) to afford the desired pyridine **3**.



N 1	COR	2a Pd cat. (10 mol%) ligand (30 mol%) oxidant (x equiv) dioxane 90 °C, 24 h		2Me	L3	O N OAd L14
entry	OR	Pd cat.	ligand	oxidant	x equiv.	yield
1	OMe	$Pd(OAc)_2$	L3	AgTFA	2.5	47%
2	OMe	$Pd(OAc)_2$	L3	none	2.5	0%
3	OMe	PdCl ₂	L3	AgTFA	2.5	10%
4	OMe	Pd(TFA) ₂	L3	AgTFA	2.5	53%
5	OMe	Pd(TFA) ₂	L3	AgOAc	2.5	trace
6	O ⁱ Pr	$Pd(OAc)_2$	L3	AgTFA	2.5	69%
7	O ⁱ Pr	$Pd(OAc)_2$	L14	AgTFA	2.5	76%
8	O ⁱ Pr	$Pd(OAc)_2$	L14	AgTFA	4.0	77%
9	O ⁱ Pr	$Pd(OAc)_2$	L14	AgTFA	5.0	85%

General procedure for substituted pyridine synthesis¹



All α_{β} -unsaturated oxime ethers used in this work were *E*-isomer. *E*- and *Z*-isomers were easily separated by flash column chromatography.

General Procedure A : To a solution of α , β -unsaturated oxime (1.0 eq.), alkene (3.0 eq.), AgTFA (5.0 eq.), and L14 (30 mol%) in dioxane (2.0 mL) was added Pd(OAc)₂ (10 mol%). The reaction mixture was stirred at 90 °C (silicone oil bath) for 24 h, then diluted with AcOEt and filtered through a Celite[®] pad (rinsed with AcOEt). The filtrate was concentrated in *vacuo*, and the crude product was purified by flash column chromatography on NH₂ silica gel.

General Procedure B : To a solution of α,β -unsaturated oxime (1.0 eq.), alkene (1.5 eq.), AgTFA (5.0 eq.), and L14 (30 mol%) in dioxane (2.0 mL) was added Pd(OAc)₂ (10 mol%). The reaction mixture was stirred at 90 °C (silicone oil bath) for 24 h, then diluted with AcOEt and filtered through a Celite[®] pad (rinsed with AcOEt). The filtrate was concentrated in *vacuo*, and the crude product was purified by flash column chromatography on NH₂ silica gel.

Investigation of the amount of catalysts and oxidant

To a solution of α , β -unsaturated oxime **18** (0.2 mmol, 1.0 eq.), pentafluorostyrene (**2r**, 0.6 mmol, 3.0 eq.), AgTFA (z equiv), and **L14** (y mol%) in dioxane (2.0 mL) was added Pd(OAc)₂ (x mol%). The reaction mixture was stirred at 90 °C (silicone oil bath), then diluted with AcOEt and filtered through a Celite[®] pad (rinsed with AcOEt). The filtrate was concentrated in *vacuo*, and the crude product was purified by flash column chromatography on NH₂ silica gel (hexane : AcOEt = 3 : 1) to afford the pyridine **74** as a white solid.



Table S2. Investigation of the amount of catalysts and oxidant.

entry	Pd(OAc) ₂ (x mol%)	L14 (y mol%)	AgTFA (z equiv)	time	yield
1	10	30	5.0	24 h	83%
2	1	3	5.0	80 h	77%
3	10	30	1.2	24 h	27%
4	10	30	2.5	24 h	44%
5	10	30	10	24 h	91%

Control experiments with specific substrates and conditions

Pyridine synthesis with Z-oxime



To a solution of (*Z*)-**11** (41 mg, 0.2 mmol, 1.0 eq.), ethyl acrylate (**2b**, 0.6 mmol, 3.0 eq.), AgTFA (1.0 mmol, 5.0 eq.), and **L14** (0.06 mmol, 30 mol%) in dioxane (2.0 mL) was added Pd(OAc)₂ (0.02 mmol, 10 mol%). The reaction mixture was stirred at 90 °C (silicone oil bath) for 24 h, then diluted with AcOEt and filtered through a Celite[®] pad (rinsed with AcOEt). The filtrate was concentrated in *vacuo*, and the crude product was purified by flash column chromatography on NH₂ silica gel (hexane : AcOEt = 3 : 1) to afford the desired pyridine **78** (21 mg, 48% yield) as a pale yellow oil. IR (KBr) 2980, 1716, 1605, 1553, 1379, 1338, 1251, 1145, 1079, 1025, 769, 696, 633 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 8.18 (d, 1H, *J* = 1.2 Hz), 7.67 (d, 2H, *J* = 8.1 Hz), 7.56–7.40 (m, 4H), 4.51 (q, 2H, *J* = 7.2 Hz), 2.72 (s, 3H), 1.46 (t, 3H, *J* = 7.2 Hz). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 165.5, 159.4, 149.6, 148.4, 137.4, 129.3, 129.1, 127.0, 124.3, 120.5, 61.9, 24.7, 14.3; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₁₅H₁₅NO₂, 241.1103; found, 241.1105.

Pyridine synthesis with *E*-oxime 11



To a solution of (*E*)-**11** (41 mg, 0.2 mmol, 1.0 eq.), ethyl acrylate (**2b**, 0.6 mmol, 3.0 eq.), AgTFA (1.0 mmol, 5.0 eq.), and **L14** (0.06 mmol, 30 mol%) in dioxane (2.0 mL) was added Pd(OAc)₂ (0.02 mmol, 10 mol%). The reaction mixture was stirred at 90 °C (silicone oil bath) for 24 h, then diluted with AcOEt and filtered through a Celite[®] pad (rinsed with AcOEt). The filtrate was concentrated in *vacuo*, and the crude product was purified by flash column chromatography on NH₂ silica gel (hexane : AcOEt = 3 : 1) to afford the pyridine **78** (30 mg, 62% yield) as a pale yellow oil.

Table S3. Competitive experiments.



To a solution of α,β -unsaturated oxime **A** (0.2 mmol, 1.0 eq.), α,β -unsaturated oxime **B** (0.2 mmol, 1.0 eq.), methyl acrylate (**2a**, 0.6 mmol, 3.0 eq.), AgTFA (1.0 mmol, 5.0 eq.), and **L14** (0.06 mmol, 30 mol%) in dioxane (2.0 mL) was added Pd(OAc)₂ (0.02 mmol, 10 mol%). The reaction mixture was stirred at 90 °C (silicone oil bath) for 60 h, then diluted with AcOEt and filtered through a Celite[®] pad (rinsed with AcOEt). The filtrate was concentrated in *vacuo*, and the crude product was purified by flash column chromatography on NH₂ silica gel (hexane : AcOEt = 2 : 1) to afford the corresponding pyridines **C** and **D** as a mixture. The product yields and the ratio of the pyridine product (**C/D**) were determined by ¹H NMR analysis of the isolated products.

Table S4. Control experiments.



To a solution of α , β -unsaturated oxime **18** (0.2 mmol, 1.0 eq.), pentafluorostyrene (**2r**, 0.6 mmol, 3.0 eq.), AgTFA (1.0 mmol, 5.0 eq.), **L14** (0.06 mmol, 30 mol%), and additive (0.2 mmol, 1.0 eq.) in

dioxane (2.0 mL) was added Pd(OAc)₂ (0.02 mmol, 10 mol%). The reaction mixture was stirred at 90 °C (silicone oil bath) for 24 h, then diluted with AcOEt and filtered through a Celite[®] pad (rinsed with AcOEt). The filtrate was concentrated in *vacuo*, and the crude product was purified by flash column chromatography on NH₂ silica gel (hexane : AcOEt = 3 : 1) to afford the desired pyridine **74** as a white solid. mp 102–103 °C; IR (KBr) 1522, 1501, 1219, 990, 772 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 7.60–7.30 (m, 5H), 7.26 (s, 1H), 3.25–3.09 (m, 4H), 2.30–2.15 (m, 2H). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 167.4, 146.3 (m), 146.0, 144.7, 143.0 (m), 139.4 (m), 138.0, 136.1 (m), 135.3, 128.7, 128.6, 128.2, 123.0, 115.8 (m), 34.6, 30.8, 23.4; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₂₀H₁₂F₅N, 361.0890; found, 361.0888.

Deuterium labeling experiments



To a solution of α , β -unsaturated oxime **18** (23 mg, 0.1 mmol, 1.0 eq.), AgTFA (0.5 mmol, 5.0 eq.), **L14** (30 mol%), and CD₃CO₂D (0.4 mL, 55 eq.) in dioxane (4.0 mL) was added Pd(OAc)₂ (0.01 mmol, 10 mol%). The reaction mixture was stirred at 90 °C (silicone oil bath) for 36 h, then diluted with AcOEt and filtered through a Celite[®] pad (rinsed with AcOEt). The filtrate was concentrated in *vacuo*, and the crude product was purified by flash column chromatography on NH₂ silica gel (hexane : AcOEt = 10 : 1) to afford the deuterated oxime (16.6 mg) as a pale yellow oil. The deuterium incorporation ratio was determined by ¹H NMR analysis of the isolated product.



To a solution of α , β -unsaturated oxime **18** (23 mg, 0.1 mmol, 1.0 eq.) in dioxane (4.0 mL) was added CD₃CO₂D (0.4 mL, 55 eq.). The reaction mixture was stirred at 90 °C (silicone oil bath) for 36 h, then diluted with AcOEt and filtered through a Celite[®] pad (rinsed with AcOEt). The filtrate was concentrated in *vacuo*, and the crude product was purified by flash column chromatography on NH₂ silica gel (hexane : AcOEt = 10 : 1) to afford the deuterated oxime (10.0 mg) as a pale yellow oil. The deuterium incorporation ratio was determined by ¹H NMR analysis of the isolated product.

Kinetic isotope effect experiment



To a solution of α , β -unsaturated oxime **18** (46 mg, 0.2 mmol, 1.0 eq.), **18**-*d*₆ (47 mg, 0.2 mmol, 1.0 eq.), pentafluorostyrene (**2r**, 0.6 mmol, 3.0 eq.), AgTFA (1.0 mmol, 5.0 eq.), and **L14** (0.06 mmol, 30 mol%) in dioxane (3.0 mL) was added Pd(OAc)₂ (0.02 mmol, 10 mol%). The reaction mixture was stirred at 90 °C (silicone oil bath) for 24 h, then diluted with AcOEt and filtered through a Celite[®] pad (rinsed with AcOEt). The filtrate was concentrated in *vacuo*, and the crude product was purified by flash column chromatography on NH₂ silica gel (hexane : AcOEt = 5 : 1). The obtained product mixture was analyzed by ¹H NMR analysis. The conversion of **74**, *X*₇₄, was determined by integration of the aromatic signals of **74**, which appeared as a multiplet (7.60–7.30 ppm). The total conversion, *X*_{total}, was determined by integration of the methylene signals of **74** and **74**-*d*₅, which appeared as multiplet at the same chemical shift (3.25–3.09 ppm for both **74** and **74**-*d*₅). Conversion of **74**-*d*₅, *X*₇₄-*d*₅, could then be determined from the following formula:

$X_{74-d5} = X_{total} - X_{74}$

 $k_{\rm H}/k_{\rm D} = X_{74}/X_{74-d5} = 2.6/1$ (the experiment was repeated two times)



Table S5. Mechanistic studies on pyridine ring formation.¹

Procedure for entry 1: To a solution of $\alpha_{,\beta}$ -unsaturated oxime **75** (60 mg, 0.25 mmol, 1.0 eq.), ethyl acrylate (**2b**, 0.75 mmol, 3.0 eq.), AgTFA (1.25 mmol, 5.0 eq.), and **L14** (0.075 mmol, 30 mol%) in dioxane (3.0 mL) was added Pd(OAc)₂ (0.025 mmol, 10 mol%). The reaction mixture was stirred at 90 °C (silicone oil bath) for 4 h, then diluted with AcOEt and filtered through a Celite[®] pad (rinsed with AcOEt). The filtrate was concentrated in *vacuo*, and the crude product was purified by flash column chromatography on NH₂ silica gel (hexane : AcOEt = 10 : 1) to afford azatriene **77** (pale yellow oil, 30 mg, 36% yield) as a mixture of *E/Z* isomers (*E* : *Z* = 1.3 : 1).

Procedure for entry 2: To a solution of α , β -unsaturated oxime **75** (95 mg, 0.4 mmol, 1.0 eq.), ethyl acrylate (**2b**, 1.2 mmol, 3.0 eq.), AgTFA (2.0 mmol, 5.0 eq.), and **L14** (0.12 mmol, 30 mol%) in dioxane (4.0 mL) was added Pd(OAc)₂ (0.04 mmol, 10 mol%). The reaction mixture was stirred at 90 °C (silicone oil bath) for 36 h, then diluted with AcOEt and filtered through a Celite[®] pad (rinsed with AcOEt). The filtrate was concentrated in *vacuo*, and the crude product was purified by flash column chromatography on NH₂ silica gel (hexane : AcOEt = 3 : 1) to afford **76** (colorless oil, 31 mg, 28% yield) and *E*-**77** (pale yellow oil, 15 mg, 11% yield).

Pyridine ring formation from 1-azatriene¹



Z-isomer of 77 (15 mg, 0.045 mmol) was dissolved in dioxane (2 mL) and stirred at 90 °C for 36 h. The reaction mixture was cooled to room temperature and concentrated in *vacuo*. The resulting residue was purified by preparative TLC (silica gel, hexane : AcOEt = 4 :1) to afford **76** (colorless oil, 10.4 mg, 84% yield) and **77** (pale yellow oil, 1.5 mg, 10% yield) as a mixture of E/Z isomers (E : Z = 3 : 1).



E-isomer of **77** (10 mg, 0.03 mmol) was dissolved in dioxane (1 mL) and stirred at 90 °C for 36 h. The reaction mixture was cooled to room temperature and concentrated in *vacuo*. The resulting residue was purified by preparative TLC (silica gel, hexane : AcOEt = 4 :1) to afford **76** (colorless oil, 1.5 mg, 18% yield) and (*E*)-**77** (7.3 mg, 73% recovery).

Preparation of ligands

Ligands L1, L2, L3, L4, L5, L9, L12, and L13 were purchased from commercially sources and used without further purification. L6, L7, L10, L11, and L14 were prepared as previously reported.¹ L8 was synthesized according to the following procedures.

6-(*tert*-butoxy)-*N*,*N*-diethylpyridin-2-amine (**L8**): To a solution of 2-(*tert*-butoxy)-6-chloropyridine (100 mg, 0.54 mmol, 1.0 eq.), diethylamine (0.11 mL, 1.1 mmol, 2.0 eq.), RuPhos (25 mg, 0.054 mmol, 10 mol%), and Cs₂CO₃ (528 mg, 1.6 mmol, 3.0 eq.) in toluene (3.0 mL) and 'BuOH (0.3 mL) was added Pd(OAc)₂ (12 mg, 0.054 mmol, 10 mol%). The reaction mixture was stirred at 100 °C (silicone oil bath) for 21 h, then diluted with AcOEt and filtered through a Celite[®] pad (rinsed with AcOEt). The filtrate was concentrated in *vacuo*, and the crude product was purified by flash column chromatography on silica gel (hexane : AcOEt = 20 : 1) to afford the title compound (95 mg, 80% yield) as a colorless oil. IR (KBr) 2974, 2929, 1589, 1573, 1490, 1434, 1397, 1360, 1297, 1247, 1179, 1156, 1078, 1046, 898, 775, 722 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 7.28 (dd, 1H, *J* = 8.1, 7.8 Hz), 5.95 (d, 1H, *J* = 8.1 Hz), 5.87 (d, 1H, *J* = 7.8 Hz), 3.46 (q, 4H, *J* = 6.9 Hz), 1.57 (s, 9H), 1.16 (t, 6H, *J* = 6.9 Hz). ¹³C {¹H} NMR (CDCl₃, 75 MHz) δ 163.0, 156.2, 139.3, 98.5, 96.3, 78.0, 42.4, 29.0, 13.1; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₁₃H₂₂N₂O, 222.1732; found, 222.1731.

Preparation of substrates

All alkenes used in this work were purchased from commercially sources and used without further purification.

 α , β -Unsaturated oximes except for 1f, 1g, 1h, 1i, 1j, 1k, 1l, 1m, 1n, and 1o were prepared as previously reported.¹

 α , β -Unsaturated oximes 1f, 1g, 1h, 1i, 1j, 1k, 1l, 1m, 1n, and 1o were synthesized according to the following procedures.



(1E,4E)-1,5-diphenylpenta-1,4-dien-3-one *O*-(*tert*-butyldimethylsilyl) oxime (**1f**): To a solution of (1E,4E)-1,5-diphenylpenta-1,4-dien-3-one oxime (200 mg, 0.80 mmol, 1.0 eq.) in CH₂Cl₂ (3 mL) were added *tert*-butyldimethylchlorosilane (133 mg, 0.88 mmol, 1.1 eq.), DMAP (10 mg, 0.08 mmol, 0.1 eq.) and imidazole (109 mg, 1.60 mmol, 2.0 eq.). The reaction mixture was stirred at room temperature for 1.5 h, then quenched

with saturated NH₄Cl aq. The aqueous layer was extracted with CHCl₃ and the combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated in *vacuo*. The crude product was purified by flash column chromatography on silica gel (hexane : AcOEt = 20 : 1) to afford the title compound (233 mg, 80% yield) as a colorless oil. IR (KBr) 2928, 2856, 1448, 1251, 967, 835, 752, 691 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 7.57–7.45 (m, 4H), 7.41–7.25 (m, 7H), 7.14 (d, 1H, *J* = 16.8 Hz), 7.09 (d, 1H, *J* = 16.8 Hz), 6.93 (d, 1H, *J* = 16.2 Hz), 1.00 (s, 9H), 0.26 (s, 6H). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 158.3, 136.7, 136.60, 136.56, 134.5, 128.82, 128.77, 128.6, 128.3, 127.2, 127.0, 122.8, 117.7, 26.2, 18.2, –5.13; HRMS (ESI-TOF) *m/z*: [M+H]⁺ Calcd for C₂₃H₃₀NOSi, 364.2097; found, 364.2092.



(1E,4E)-1,5-diphenylpenta-1,4-dien-3-one *O*-(*tert*-butyldimethylsilyl) oxime (**1g**): To a solution of (1E,4E)-1,5-diphenylpenta-1,4-dien-3-one oxime (100 mg, 0.40 mmol, 1.0 eq.) in THF (2 mL) were added NaH (63% dispersion in mineral oil, 24 mg, 0.60 mmol, 1.5 eq.) and *tert*-butyldiphenylchlorosilane (220 mg, 0.80 mmol, 2.0 eq.). The reaction mixture was stirred at room temperature overnight, then quenched with

water. The aqueous layer was extracted with AcOEt and the combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated in *vacuo*. The crude product was purified by flash column chromatography on silica gel (hexane : AcOEt = 10 : 1) to afford the title compound (201 mg, quant.) as a colorless oil. IR (KBr) 3071, 2931, 2857, 1471, 1428, 1262, 1113, 969, 832,

754, 695, 610, 560, 505 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 7.80–7.75 (m, 4H), 7.65–7.56 (m, 3H), 7.50–7.22 (m, 14H), 7.18 (d, 1H, *J* = 16.8 Hz), 7.10 (d, 1H, *J* = 16.8 Hz), 6.92 (d, 1H, *J* = 16.2 Hz), 1.16 (s, 9H). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 159.0, 137.1, 136.6, 136.5, 135.5, 135.1, 133.6, 129.6, 129.0, 128.9, 128.7, 128.4, 127.6, 127.3, 127.0, 122.7, 117.6, 27.2, 19.5; HRMS (ESI-TOF) *m/z*: [M+Na]⁺ Calcd for C₃₃H₃₃NNaOSi, 510.2229; found, 510.2216.



(1E,4E)-1,5-diphenylpenta-1,4-dien-3-one *O*-triisopropylsilyl oxime (**1h**): To a solution of (1E,4E)-1,5-diphenylpenta-1,4-dien-3-one oxime (200 mg, 0.80 mmol, 1.0 eq.) in CH₂Cl₂ (3 mL) were added triisopropylsilyl chloride (170 mg, 0.88 mmol, 1.1 eq.), DMAP (10 mg, 0.08 mmol, 0.1 eq.) and imidazole (109 mg, 1.60 mmol, 2.0 eq.). The

reaction mixture was stirred at room temperature for 1.5 h, then quenched with saturated NH₄Cl aq. The aqueous layer was extracted with CHCl₃ and the combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated in *vacuo*. The crude product was purified by flash column chromatography on silica gel (hexane : AcOEt = 20 : 1) to afford the title compound (241 mg, 74% yield) as a pale yellow oil. IR (KBr) 3026, 2943, 2865, 1635, 1493, 1462, 1448, 1345, 1260, 1200, 967, 882, 826, 754, 690, 460 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 7.60–7.49 (m, 4H), 7.45–7.28 (m, 7H), 7.13 (d, 1H, *J* = 16.2 Hz), 7.10 (d, 1H, *J* = 16.8 Hz), 6.93 (d, 1H, *J* = 16.2 Hz), 1.40–1.20 (m, 3H), 1.13 (d, 18H, *J* = 6.9 Hz). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 157.9, 136.8, 136.7, 136.2, 134.1, 128.8, 128.7, 128.2, 127.2, 126.9, 123.0, 117.7, 18.0, 11.9; HRMS (ESI-TOF) *m/z*: [M+H]⁺ Calcd for C₂₆H₃₆NOSi, 406.2566; found, 406.2560.



(1E,4E)-1,5-diphenylpenta-1,4-dien-3-one *O*-pivaloyl oxime (1i): To a solution of (1E,4E)-1,5-diphenylpenta-1,4-dien-3-one oxime (300 mg, 1.20 mmol, 1.0 eq.) in THF (6 mL) were added NaH (63% dispersion in mineral oil, 96 mg, 2.40 mmol, 2.0 eq.) and pivaloyl chloride (0.22 mL, 1.80 mmol, 1.5 eq.). The reaction mixture was stirred at room temperature

for 30 min, then quenched with 1M NaOH aq. The aqueous layer was extracted with AcOEt and the combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated in *vacuo*. The crude product was purified by flash column chromatography on silica gel (hexane : AcOEt = 4 : 1) to afford the title compound (388 mg, 96% yield) as a pale yellow solid. mp 105–106 °C; IR (KBr) 2973, 1754, 1636, 1577, 1478, 1448, 1343, 1273, 1202, 1105, 1026, 970, 923, 878, 755, 693 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 7.55–7.51 (m, 4H), 7.45–7.29 (m, 7H), 7.23 (d, 1H, *J* = 16.5

Hz), 7.19 (d, 1H, J = 16.5 Hz), 7.03 (d, 1H, J = 16.2 Hz), 1.34 (s, 9H). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 174.9, 161.1, 139.8, 138.9, 135.8, 135.4, 129.7, 129.2, 129.0, 128.8, 127.4, 127.3, 120.9, 116.8, 38.9, 27.3; HRMS (EI-quadrupole) m/z: [M]⁺ Calcd for C₂₂H₂₃NO₂, 333.1729; found, 333.1716.



(1E,4E)-1,5-diphenylpenta-1,4-dien-3-one *O*-pentafluorophenyl oxime (1j): To a solution of (1E,4E)-1,5-diphenylpenta-1,4-dien-3-one oxime (100 mg, 0.40 mmol, 1.0 eq.) in DMF (3 mL) were added NaH (63% dispersion in mineral oil, 32 mg, 0.60 mmol, 1.5 eq.) and hexafluorobenzene (0.1 mL, 0.80 mmol, 2.0 eq.). The reaction mixture was stirred at room temperature for 1 h, then quenched with water. The aqueous layer was extracted with AcOEt and the combined organic layers

were washed with brine, dried over Na₂SO₄, filtered and concentrated in *vacuo*. The crude product was purified by flash column chromatography on silica gel (hexane : AcOEt = 10 : 1) to afford the title compound (133 mg, 80% yield) as a pale yellow solid. mp 103–104 °C; IR (KBr) 3027, 1634, 1577, 1515, 1465, 1448, 1344, 1201, 996, 969, 874, 854, 755, 691, 521 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 7.65–7.30 (m, 11H), 7.23 (d, 1H, *J* = 15.9 Hz), 7.19 (d, 1H, *J* = 16.8 Hz), 6.86 (d, 1H, *J* = 15.9 Hz). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 159.4, 140.0, 138.1, 135.8, 135.5, 129.8, 129.2, 128.9, 128.8, 127.7, 127.3, 119.6, 116.1; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₂₃H₁₄F₅NO, 415.0996; found, 415.0987.



(1E,4E)-1,5-diphenylpenta-1,4-dien-3-one *O*-(pentafluorophenyl)metyl oxime (**1k**): To a solution of *O*-(pentafluorobenzyl)hydroxylamine hydrochloride (57 mg, 0.23 mmol, 1.1 eq.) and pyridine (42 mg, 0.53 mmol, 2.5 eq.) in MeOH (2 mL) was added *trans,trans*-dibenzalacetone (50 mg, 0.21 mmol, 1.0 eq.). The reaction mixture was stirred at room temperature overnight, then quenched with saturated NH₄Cl aq. The aqueous layer was extracted with AcOEt and the combined organic layers

were washed with brine, dried over Na₂SO₄, filtered and concentrated in *vacuo* to afford the title compound (89 mg, 99% yield) as a white solid. mp 122–123 °C; IR (KBr) 1655, 1521, 1506, 1448, 1305, 1127, 1025, 962, 941, 755, 692 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 7.53–7.46 (m, 4H), 7.44–7.30 (m, 6H), 7.19 (d, 1H, *J* = 16.8 Hz), 7.12 (d, 1H, *J* = 16.2 Hz), 7.04 (d, 1H, *J* = 16.8 Hz), 6.83 (d, 1H, *J* = 16.2 Hz), 5.30 (s, 2H). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 155.2, 147.6 (m), 144.1 (m), 139.0 (m), 137.7, 136.3, 136.0, 135.5, 129.0, 128.8 (several signals overlapped.), 127.2, 127.0 (several signals overlapped.), 121.8, 117.0, 111.0 (m), 63.0; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₂₄H₁₆F₅NO, 429.1152; found, 429.1151.



(1E,4E)-1,5-diphenylpenta-1,4-dien-3-one *O*-(pyridin-2-yl)methyl oxime (11): To a solution of (1E,4E)-1,5-diphenylpenta-1,4-dien-3-one oxime (300 mg, 1.20 mmol, 1.0 eq.) in DMF (6 mL) were added NaH (63% dispersion in mineral oil, 120 mg, 3.0 mmol, 2.5 eq.) and 2-(bromomethyl)pyridine hydrobromide (364 mg, 1.4 mmol, 1.2 eq.). The reaction mixture was stirred at room temperature for 2.5 h, then quenched

with water. The aqueous layer was extracted with AcOEt and the combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated in *vacuo*. The crude product was purified by flash column chromatography on silica gel (hexane : AcOEt = 3 : 1) to afford the title compound (329 mg, 80% yield) as a pale yellow solid. mp 56–57 °C; IR (KBr) 3024, 1590, 1493, 1435, 1356, 1098, 1059, 969, 899, 754, 692 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 8.60 (dd, 1H, *J* = 3.9, 1.8 Hz), 7.70 (ddd, 1H, *J* = 7.8, 7.8, 1.8 Hz), 7.57–7.26 (m, 12H), 7.23–7.18 (m, 1H), 7.13 (d, 1H, *J* = 16.2 Hz), 7.11 (d, 1H, *J* = 16.5 Hz), 6.89 (d, 1H, *J* = 16.2 Hz), 5.40 (s, 2H). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 158.3, 155.0, 149.2, 137.4, 136.6, 136.4, 136.2, 135.2, 129.0, 128.8, 128.7, 128.5, 127.3, 127.0, 122.4, 122.2, 121.7, 117.4, 77.0; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₂₃H₂₀N₂O, 340.1576; found, 340.1581.



(1E,4E)-1,5-diphenylpenta-1,4-dien-3-one *O*-(trimethylsilyl)methyl oxime (**1m**): To a solution of (1*E*,4*E*)-1,5-diphenylpenta-1,4-dien-3-one oxime (150 mg, 0.60 mmol, 1.0 eq.) in THF (3 mL) were added NaH (63% dispersion in mineral oil, 36 mg, 0.90 mmol, 1.5 eq.) and chloromethyl trimethylsilane (0.17 mL, 1.20 mmol, 2.0 eq.). The reaction mixture was stirred at 70 °C (silicone oil bath) for 21 h, then quenched with water. The

aqueous layer was extracted with AcOEt and the combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated in *vacuo*. The crude product was purified by flash column chromatography on silica gel (hexane : AcOEt = 10 : 1) to afford the title compound (183 mg, 92% yield) as a pale yellow oil. IR (KBr) 2955, 1633, 1494, 1448, 1248, 1027, 968, 854, 754, 691 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 7.55–7.45 (m, 4H), 7.39–7.22 (m, 7H), 7.12 (d, 1H, *J* = 16.2 Hz), 7.09 (d, 1H, *J* = 16.8 Hz), 6.87 (d, 1H, *J* = 16.2 Hz), 4.02 (s, 2H), 0.15 (s, 9H). ¹³C {¹H} NMR (CDCl₃, 75 MHz) δ 153.6, 136.8, 136.7, 136.5, 134.3, 128.83, 128.78, 128.7, 128.3, 127.1, 126.9, 122.7, 117.4, 69.1, –2.68; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₂₁H₂₅NOSi, 335.1705; found, 335.1703.



(1E,4E)-1,5-diphenylpenta-1,4-dien-3-one *O*-methoxymethyl oxime (**1n**): To a solution of (1E,4E)-1,5-diphenylpenta-1,4-dien-3-one oxime (200 mg, 0.80 mmol, 1.0 eq.) in DMF (3 mL) were added NaH (63% dispersion in mineral oil, 38 mg, 0.96 mmol, 1.2 eq.) and chloromethyl methyl ether (0.12 mL, 1.60 mmol, 2.0 eq.). The reaction mixture was stirred at room temperature for 1 h, then quenched with water. The

aqueous layer was extracted with AcOEt and the combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated in *vacuo*. The crude product was purified by flash column chromatography on silica gel (hexane : AcOEt = 5 : 1) to afford the title compound (162 mg, 69% yield) as a colorless oil. IR (KBr) 2933, 1634, 1576, 1494, 1448, 1392, 1345, 1209, 1154, 1086, 997, 970, 924, 896, 855, 755, 692 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 7.60–7.49 (m, 4H), 7.40–7.29 (m, 7H), 7.17 (d, 1H, *J* = 16.2 Hz), 7.08 (d, 1H, *J* = 16.8 Hz), 6.92 (d, 1H, *J* = 16.2 Hz), 5.24 (s, 2H), 3.50 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 155.7, 137.6, 136.4, 136.1, 135.6, 129.1, 128.8, 128.7, 128.5, 127.3, 127.0, 122.2, 117.4, 98.8, 56.4; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₁₉H₁₉NO₂, 293.1416; found, 293.1415.



(1E,4E)-1,5-diphenylpenta-1,4-dien-3-one O-((2-(trimethylsilyl)ethoxy)methyl) oxime (**1o**): To a solution of (1E,4E)-1,5diphenylpenta-1,4-dien-3-one oxime (200 mg, 0.80 mmol, 1.0 eq.) in DMF (4 mL) were added NaH (63% dispersion in mineral oil, 48 mg, 1.20 mmol, 1.5 eq.) and 2-(chloromethoxy)ethyltrimethylsilane (267 mg, 1.6 mmol, 2.0 eq.). The reaction mixture was stirred at room temperature for 1 h, then quenched with water. The aqueous layer was extracted with

AcOEt and the combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated in *vacuo*. The crude product was purified by flash column chromatography on silica gel (hexane : AcOEt = 20 : 1) to afford the title compound (260 mg, 85% yield) as a colorless oil. IR (KBr) 2952, 1448, 1248, 1104, 995, 857, 835, 754, 692 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 7.55–7.45 (m, 4H), 7.39–7.24 (m, 7H), 7.14 (d, 1H, *J* = 16.2 Hz), 7.05 (d, 1H, *J* = 16.8 Hz), 6.90 (d, 1H, *J* = 16.2 Hz), 5.27 (s, 2H), 3.79–3.73 (m, 2H), 1.02–0.95 (m, 2H), 0.00 (s, 9H). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 155.3, 137.3, 136.4, 136.1, 135.4, 129.2, 128.9, 128.7, 128.5, 127.8, 127.5, 122.2, 117.5, 97.3, 66.4, 18.0, –1.44; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₂₃H₂₉NO₂Si, 379.1968; found, 379.1964.

General procedure for the synthesis of *O*-isopropyl α,β -unsaturated oxime ethers¹



To a solution of $\alpha \beta$ -unsaturated ketone (1.0 eq.) in MeOH (0.5 M) were added hydroxylamine hydrochloride (1.5 eq.) and pyridine (2.0 eq.). The reaction mixture was stirred at 60 °C (silicone oil bath) for 1 h, then quenched with saturated NH₄Cl. The aqueous layer was extracted with AcOEt and the combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated in *vacuo*. The resulting residue was dissolved in DMF (0.3 M) and cooled to 0 °C. After the addition of NaH (63% dispersion in mineral oil, 2.0 eq.) and 2-iodopropane (1.3 eq.) at 0 °C, the reaction mixture was stirred at room temperature for 30 min, then quenched with water. The aqueous layer was extracted with AcOEt and the combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated in *vacuo*. The crude product was purified by flash column chromatography on silica gel to afford the desired *O*-isopropyl $\alpha \beta$ -unsaturated oxime ethers. *E*- and *Z*-isomers were easily separated by flash column chromatography and the configuration of oximes were determined by ¹H NMR analysis.



(2Z,3E)-4-phenylbut-3-en-2-one *O*-isopropyl oxime (*Z*-11): Following the general procedure for unsymmetrical α,β -unsaturated oxime ether synthesis with (*E*)-4-phenylbut-3-en-2-one (1.0 g, 6.84 mmol), purification by flash column chromatography on silica gel (hexane : CH₂Cl₂ = 3 : 1) afforded (*E*)-11¹ (colorless oil, 622 mg, 45% yield) and a small amount of (*Z*)-11 (colorless oil, 200 mg, 14% yield). The configuration of oximes were determined by ¹H NMR analysis (The vinylene peak of *Z*-oxime was observed at a lower magnetic field than that of *E*-oxime.).

(*E*)-11: ¹H NMR (CDCl₃, 300 MHz) δ 7.50–7.44 (m, 2H), 7.37–7.25 (m, 3H), 6.90–6.75 (m, 2H), 4.39 (m, 1H), 2.07 (s, 3H), 1.29 (d, 6H, J = 6.3 Hz). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 154.9, 136.7, 132.2, 128.7, 128.1, 126.7, 126.6, 75.7, 21.8, 10.3.

(*Z*)-**11**: IR (KBr) 2973, 2900, 1577, 1493, 1465, 1379, 1368, 1341, 1325, 1301, 1147, 1119, 991, 982, 956, 912, 874, 753, 694, 626, 616, 589, 516 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 7.54–7.50 (m, 2H), 7.50 (d, 1H, *J* = 16.8 Hz), 7.40–7.30 (m, 3H), 6.89 (d, 1H, *J* = 16.8 Hz), 4.37 (m, 1H), 2.11 (s, 3H), 1.28 (d, 6H, *J* = 6.3 Hz). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 151.6, 136.5, 135.5, 128.8, 128.7, 127.4,

117.9, 75.3, 21.7, 17.0; HRMS (EI-quadrupole) m/z: [M]⁺ Calcd for C₁₃H₁₇NO, 203.1310; found, 203.1307.





= 10 : 1) afforded the title compound (white solid, 1.13 g, 81% yield). mp 76–77 °C; IR (KBr) 2971, 2933, 2835, 1605, 1509, 1463, 1367, 1301, 1250, 1177, 1146, 1122, 1035, 969, 889, 835, 749, 531 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 7.26 (d, 2H, *J* = 8.4 Hz), 6.88 (s, 1H), 6.86 (d, 2H, *J* = 8.4 Hz), 4.45–4.35 (m, 1H), 3.81 (s, 3H), 2.70–2.60 (m, 2H), 2.59–2.56 (m, 2H), 1.70–1.58 (m, 4H), 1.29 (d, 6H, *J* = 6.0 Hz). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 159.0, 158.5, 133.5, 131.1, 129.8, 126.6, 113.4, 75.1, 55.2, 29.0, 25.8, 24.9, 23.3, 21.9; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₁₇H₂₃NO₂, 273.1729; found, 273.1728.



(1*E*)-2-(4-methoxybenzylidene)cycloheptan-1-one *O*-isopropyl oxime (37): Following the general procedure for the synthesis of *O*-isopropyl α,β unsaturated oxime ethers with (*E*)-2-((*E*)-4methoxybenzylidene)cycloheptan-1-one oxime (1.31 g, 5.69 mmol), purification by flash column chromatography on silica gel (hexane : AcOEt

= 30 : 1) afforded the title compound (colorless oil, 916 mg, 56% yield). IR (KBr) 2971, 2928, 2854, 1606, 1573, 1509, 1455, 1368, 1301, 1251, 1176, 1150, 1123, 1035, 969, 888, 828, 750, 532 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 7.30 (d, 2H, *J* = 8.4 Hz), 6.87 (d, 2H, *J* = 8.4 Hz), 6.67 (s, 1H), 4.45–4.38 (m, 1H), 3.81 (s, 3H), 2.64–2.56 (m, 4H), 1.70–1.65 (m, 6H), 1.27 (d, 6H, *J* = 6.0 Hz). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 163.9, 158.4, 138.0, 130.4, 129.9, 127.3, 113.5, 74.9, 55.2, 30.5, 30.0, 28.1, 27.7, 24.9, 21.9; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₁₈H₂₅NO₂, 287.1885; found, 287.1886.



(2E,3E)-3-methyl-4-phenylbut-3-en-2-one *O*-isopropyl oxime (**38**): Following the general procedure for the synthesis of *O*-isopropyl α,β -unsaturated oxime ethers with (2E,3E)-3-methyl-4-phenylbut-3-en-2-one oxime (200 mg, 1.25 mmol), purification by flash column chromatography on silica gel (hexane : AcOEt = 30 : 1) afforded the title compound (colorless oil, 230 mg, 85% yield).

IR (KBr) 2973, 1440, 1370, 1324, 1276, 1150, 1124, 1019, 975, 915, 857, 742, 698, 579, 506 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 7.40–7.24 (m, 5H), 6.83 (s, 1H), 4.44–4.35 (m, 1H), 2.10 (s, 3H), 2.09 (s, 3H), 1.28 (d, 6H, J= 6.3 Hz). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 155.9, 137.6, 135.6, 129.6, 129.3,

128.1, 126.8, 75.4, 21.7, 14.2, 10.9; HRMS (EI-quadrupole) m/z: [M]⁺ Calcd for C₁₄H₁₉NO, 217.1467; found, 217.1468.



(2E,3E)-4-cyclohexylbut-3-en-2-one O-isopropyl oxime (39): Following the general procedure for the synthesis of O-isopropyl α,β -unsaturated oxime ethers with (2E,3E)-4-cyclohexylbut-3-en-2-one oxime (500 mg, 3.28 mmol), purification by flash column chromatography on silica gel (hexane : $CH_2Cl_2 =$ 4 : 1) afforded the title compound (colorless oil, 326 mg, 48% yield). IR (KBr)

2973, 2925, 2852, 1448, 1369, 1323, 1150, 1123, 965, 750, 581 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 6.10 (dd, 1H, J = 16.2, 1.8 Hz), 5.95 (dd, 1H, J = 16.2, 6.6 Hz), 4.36–4.27 (m, 1H), 2.15–2.00 (m, 1H), 1.92 (s, 3H), 1.80–1.60 (m, 5H), 1.40–1.10 (m, 5H), 1.24 (d, 6H, J = 6.3 Hz). ¹³C{¹H} NMR (CDCl₃, 75 MHz) & 155.0, 140.8, 125.5, 75.2, 40.9, 32.6, 26.1, 25.9, 21.7, 10.2; HRMS (EIquadrupole) m/z: [M]⁺ Calcd for C₁₃H₂₃NO, 209.1780; found, 209.1779.



(2E,3E)-5-(benzyloxy)pent-3-en-2-one O-isopropyl oxime (40): Following the general procedure for the synthesis of O-isopropyl α,β -unsaturated oxime ethers with (2E,3E)-5-(benzyloxy)pent-3-en-2-one oxime (1.05 g, 5.52 mmol), purification by flash column chromatography on silica gel (hexane : AcOEt = 30 : 1) afforded the title compound (pale yellow oil, 461 mg, 34% yield). IR (KBr) 2974, 1455, 1369, 1274, 1120, 970, 749, 698 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 7.40–7.28 (m, 5H), 6.37 (dd, 1H, J = 16.2, 1.5 Hz), 6.09 (td, 1H, J = 16.2, 6.0 Hz), 4.53 (s, 3H), 4.36-4.30 (m, 1H), 4.14 (dd, 1H),1H, J = 6.0, 1.5 Hz), 1.95 (s, 3H), 1.25 (d, 6H, J = 6.0 Hz). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 154.0,

138.1, 130.4, 130.0, 128.4, 127.7, 127.6, 75.5, 72.3, 70.3, 21.7, 10.2; HRMS (EI-quadrupole) m/z: $[M]^+$ Calcd for C₁₅H₂₁NO₂, 247.1572; found, 247.1577.



(2E,3E,5E)-6-(4-methoxyphenyl)hexa-3,5-dien-2-one *O*-isopropyl oxime (41): Following the general procedure for the synthesis of Oisopropyl α,β -unsaturated oxime ethers with (2E,3E,5E)-6-(4methoxyphenyl)hexa-3,5-dien-2-one oxime (1.08 g, 5.33 mmol), purification by flash column chromatography on silica gel (hexane :

AcOEt = 10:1) afforded the title compound (pale yellow solid, 605 mg, 44% yield). mp 85–86 °C; IR (KBr) 2968, 2927, 1599, 1511, 1457, 1367, 1257, 1151, 1120, 1027, 990, 971, 840, 818, 806, 749, 539, 516 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 7.36 (d, 2H, J = 8.7 Hz), 6.86 (d, 2H, J = 8.7 Hz), 6.80-6.58 (m, 3H), 6.36 (d, 1H, J = 15.6 Hz), 4.39 - 4.30 (m, 1H), 3.81 (s, 3H), 2.00 (s, 3H), 1.27 (d, 6H, J= 6.3 Hz). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 159.5, 155.0, 133.8, 133.0, 129.8, 129.3, 127.8, 126.7, 114.1, 75.6, 55.3, 21.7, 10.3; HRMS (EI-quadrupole) m/z: [M]⁺ Calcd for C₁₆H₂₁NO₂, 259.1572; found, 259.1575.

Pd-catalyzed substituted pyridine synthesis¹



methyl (*E*)-4-phenyl-6-styrylpicolinate (**3**): Following the general procedure A for pyridine synthesis with α , β -unsaturated oxime **1b** (50 mg, 0.17 mmol) and methyl acrylate (**2a**), purification by flash column chromatography (hexane : AcOEt = 5 : 1) afforded the title compound (white solid, 46 mg, 85% yield). ¹H NMR (CDCl₃, 300 MHz) δ 8.23 (d, 1H, *J* = 1.5 Hz), 7.85 (d, 1H, *J* = 1.5 Hz), 7.76–7.69 (m, 2H), 7.67–7.58 (m, 3H), 7.57–7.45 (m, 3H), 7.44–7.28 (m, 4H), 4.06 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 166.0, 156.8, 150.1, 148.4, 137.4, 136.3, 134.3, 129.5, 129.2, 128.8, 128.6, 127.6, 127.3, 127.1, 122.1, 121.5, 53.0; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₂₁H₁₇NO₂, 315.1259; found, 315.1247.



methyl (*E*)-6-(4-methylstyryl)-4-(*p*-tolyl)picolinate (**21**): Following the general procedure A for pyridine synthesis with α , β -unsaturated oxime **6** (64 mg, 0.20 mmol) and methyl acrylate (**2a**), purification by flash column chromatography (hexane : AcOEt = 4 : 1) afforded the title compound (white solid, 63 mg, 91% yield). ¹H NMR (CDCl₃, 300 MHz) δ 8.20 (d, 1H, *J* = 1.8 Hz), 7.82 (d, 1H, *J* = 1.8 Hz), 7.70–7.61 (m, 3H), 7.52 (d, 2H, *J* = 8.1 Hz), 7.35–7.27 (m, 3H), 7.20 (d, 2H, *J* = 7.8 Hz), 4.05 (s, 3H), 2.43 (s, 3H), 2.37 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 166.1, 156.9, 149.9, 148.4, 139.7, 138.7, 134.5, 134.1, 133.6, 129.9, 129.5, 127.2, 126.9, 126.8, 121.7, 121.1, 53.0, 21.3, 21.2; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₂₃H₂₁NO₂, 343.1572; found, 343.1559.



methyl (*E*)-4-(4-methoxyphenyl)-6-(4-methoxystyryl)picolinate (**22**): Following the general procedure A for pyridine synthesis with α , β -unsaturated oxime **7** (70 mg, 0.20 mmol) and methyl acrylate (**2a**), purification by flash column chromatography (hexane : AcOEt = 3 : 1) afforded the title compound (pale yellow solid, 64 mg, 85% yield). ¹H NMR (CDCl₃, 300 MHz) δ 8.17 (d, 1H, *J* = 1.8 Hz), 7.77 (d, 1H, *J* = 1.8 Hz), 7.69 (d, 2H, *J* = 8.7 Hz), 7.63 (d, 1H, *J* = 16.5 Hz), 7.56 (d, 2H, *J* = 8.7 Hz), 7.21 (d, 1H, *J* = 16.5 Hz), 7.04 (d, 2H, *J* = 8.7 Hz), 6.93 (d, 2H, *J* = 8.7 Hz), 4.05 (s, 3H), 3.88 (s, 3H), 3.84 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 166.2, 160.8, 160.1, 157.1, 149.4, 148.3, 133.7, 129.7, 129.1, 128.6, 128.3, 125.6, 121.2, 120.6, 114.6, 114.2, 55.4, 55.3, 53.0; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₂₃H₂₁NO₄, 375.1471; found, 375.1467.



methyl (*E*)-4-(4-fluorophenyl)-6-(4-fluorostyryl)picolinate (**23**): Following the general procedure A for pyridine synthesis with α , β -unsaturated oxime **8** (65 mg, 0.20 mmol) and methyl acrylate (**2a**), purification by flash column chromatography (hexane : AcOEt = 3 : 1) afforded the title compound (pale yellow oil, 45 mg, 65% yield). H NMR (CDCl₃, 300 MHz) δ 8.18 (d, 1H, *J* = 1.5 Hz), 7.77 (d, 1H, *J* = 1.5 Hz), 7.74–7.63 (m, 3H), 7.61–7.55 (m, 2H), 7.28–7.18 (m, 3H), 7.13–7.05 (m, 2H), 4.06 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 165.9, 165.4, 164.6, 162.0, 161.3, 156.7, 149.1, 148.6, 133.5, 133.3, 132.5, 132.4, 129.0, 128.9, 128.8, 127.2, 122.0, 121.3, 116.5, 116.2, 116.0, 115.7, 53.1; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₂₁H₁₅F₂NO₂, 351.1071; found, 351.1058.



methyl (*E*)-4-(4-chlorophenyl)-6-(4-chlorostyryl)picolinate (**24**): Following the general procedure A for pyridine synthesis with α,β -unsaturated oxime **9** (43 mg, 0.12 mmol) and methyl acrylate (**2a**), purification by flash column chromatography (hexane : AcOEt = 3 : 1) afforded the title compound (pale yellow solid, 33 mg, 70% yield). ¹H NMR (CDCl₃, 300 MHz) δ 8.19 (d, 1H, *J* = 1.5 Hz), 7.77 (d, 1H, *J* = 1.5 Hz), 7.71–7.63 (m, 3H), 7.57–7.48 (m, 4H), 7.36 (d, 2H, *J* = 8.4 Hz), 7.30 (d, 1H, *J* = 16.2 Hz), 4.06 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 165.8, 156.6, 149.0, 148.7, 135.9, 135.8, 134.7, 134.5, 133.2, 129.5, 129.0, 128.4, 128.3, 127.9, 122.1, 121.3, 53.1; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₂₁H₁₅Cl₂NO₂, 383.0480; found, 383.0487.



methyl (*E*)-4-(4-(trifluoromethyl)phenyl)-6-(4-(trifluoromethyl)styryl)picolinate (**25**): Following the general procedure A for pyridine synthesis with $\alpha_{,\beta}$ -unsaturated oxime **10** (43 mg, 0.10 mmol) and methyl acrylate (**2a**), purification by flash column chromatography (hexane : AcOEt = 3 : 1) afforded the title compound (pale yellow solid, 30 mg, 66% yield). ¹H NMR (CDCl₃, 300 MHz) δ 8.26 (d, 1H, *J* = 1.8 Hz), 7.85–7.63 (m, 10H), 7.42 (d, 1H, *J* = 16.2 Hz), 4.08 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 165.6, 156.3, 148.9, 140.8, 139.6, 133.2, 131.8, 131.4, 130.6, 130.2, 129.5, 127.6, 127.4, 126.3, 126.2, 125.8, 122.8, 122.0, 53.2; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₂₃H₁₅F₆NO₂, 451.1007; found, 451.1020.



methyl 6-methyl-4-phenylpicolinate (**26**): Following the general procedure A for pyridine synthesis with α , β -unsaturated oxime **11** (41 mg, 0.20 mmol) and methyl acrylate (**2a**), purification by flash column chromatography (hexane : AcOEt = 3 : 1) afforded the title compound (pale yellow oil, 31 mg, 68% yield). ¹H NMR (CDCl₃, 300 MHz) δ 8.21 (d, 1H, *J* = 1.2 Hz), 7.68 (dd, 2H, *J* = 9.0, 1.5 Hz), 7.58–7.40 (m, 4H), 4.03 (s, 3H), 2.73 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 166.1, 159.5, 149.7, 148.0, 137.3, 129.4, 129.1, 127.0, 124.5, 120.6, 53.0, 24.7; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₁₄H₁₃NO₂, 227.0946; found, 227.0951.



methyl 6-methyl-4-(*p*-tolyl)picolinate (**27**): Following the general procedure A for pyridine synthesis with α , β -unsaturated oxime **12** (43 mg, 0.20 mmol) and methyl acrylate (**2a**), purification by flash column chromatography (hexane : AcOEt = 3 : 1) afforded the title compound (pale yellow solid, 39 mg, 80% yield). ¹H NMR (CDCl₃, 300 MHz) δ 8.20 (d, 1H, *J* = 1.8 Hz), 7.59 (d, 2H, *J* = 8.1 Hz), 7.55 (d, 1H, *J* = 1.8 Hz), 7.30 (d, 2H, *J* = 8.1 Hz), 4.03 (s, 3H), 2.71 (s, 3H), 2.42 (s, 3H). ¹³C {¹H} NMR (CDCl₃, 75 MHz) δ 166.1, 159.4, 149.6, 148.0, 139.6, 134.4, 129.9, 126.8, 124.2, 120.4, 52.9, 24.7, 21.2; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₁₅H₁₅NO₂, 241.1103; found, 241.1096.



methyl 4-(4-methoxyphenyl)-6-methylpicolinate (**28**): Following the general procedure A for pyridine synthesis with α , β -unsaturated oxime **13** (41 mg, 0.20 mmol) and methyl acrylate (**2a**), purification by flash column chromatography (hexane : AcOEt = 2 : 1) afforded the title compound (pale yellow solid, 39 mg, 75% yield). ¹H NMR (CDCl₃, 300 MHz) δ 8.17 (d, 1H, *J* = 1.2 Hz), 7.64 (d, 2H, *J* = 8.7 Hz), 7.52 (d, 1H, *J* = 1.2 Hz), 7.02 (d, 2H, *J* = 8.7 Hz), 4.03 (s, 3H), 3.87 (s, 3H), 2.70 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 166.2, 160.7, 159.3, 149.1, 147.9, 129.5, 128.2, 123.7, 120.0, 114.5, 55.3, 52.9, 24.7; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₁₅H₁₅NO₃, 257.1052; found, 257.1057.



methyl 4-(4-chlorophenyl)-6-methylpicolinate (**29**): Following the general procedure A for pyridine synthesis with α , β -unsaturated oxime **14** (48 mg, 0.20 mmol) and methyl acrylate (**2a**), purification by flash column chromatography (hexane : AcOEt = 1 : 1) afforded the title compound (white solid, 34 mg, 64% yield). ¹H NMR (CDCl₃, 300 MHz) δ 8.17 (d, 1H, *J* = 1.2 Hz), 7.62 (d, 2H, *J* = 8.7 Hz), 7.53 (d, 1H, *J* = 1.2 Hz), 7.48 (d, 2H, *J* = 8.7 Hz), 4.03 (s, 3H), 2.73 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 165.9, 159.7, 148.5, 148.2, 135.8, 135.7, 129.4, 128.3, 124.2, 120.4, 53.0, 24.7; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₁₄H₁₂CINO₂, 261.0557, 263.0527; found, 261.0562, 263.0522.



methyl 4-(4-chlorophenyl)-6-propylpicolinate (**30**): Following the general procedure A for pyridine synthesis with α , β -unsaturated oxime **15** (53 mg, 0.20 mmol) and methyl acrylate (**2a**), purification by flash column chromatography (hexane : AcOEt = 10 : 1) afforded the title compound (white solid, 37 mg, 64% yield). ¹H NMR (CDCl₃, 300 MHz) δ 8.17 (d, 1H, *J* = 1.2 Hz), 7.62 (d, 2H, *J* = 8.7 Hz), 7.51 (d, 1H, *J* = 1.2 Hz), 7.48 (d, 2H, *J* = 8.7 Hz), 4.03 (s, 3H), 2.94 (t, 2H, *J* = 8.1 Hz), 1.87–1.78 (m, 2H), 1.02 (t, 3H, *J* = 7.5 Hz). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 166.1, 163.7, 148.4, 148.3,

136.0, 135.7, 129.4, 128.3, 123.5, 120.6, 53.0, 40.5, 23.4, 13.9; HRMS (EI-quadrupole) m/z: [M]^{\top} Calcd for C₁₆H₁₆ClNO₂, 289.0870; found, 289.0871.



methyl 4-(dibenzo[*b*,*d*]thiophen-3-yl)-6-methylpicolinate (**31**): Following the general procedure A for pyridine synthesis with α , β -unsaturated oxime **16** (62 mg, 0.20 mmol) and methyl acrylate (**2a**), purification by flash column chromatography (hexane : AcOEt = 2 : 1) afforded the title compound (pale yellow solid, 32 mg, 48% yield). ¹H NMR (CDCl₃, 300 MHz) δ 8.42 (d, 1H, *J* = 1.5 Hz), 8.32 (d, 1H, *J* = 1.5 Hz), 8.29–8.22 (m, 1H), 7.96 (d, 1H, *J* = 8.4 Hz), 7.92–7.85 (m, 1H), 7.75 (dd, 1H, *J* = 8.4, 1.8 Hz), 7.67 (d, 1H, *J* = 1.8 Hz), 7.55–7.47 (m, 2H), 4.06 (s, 3H), 2.77 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 166.1, 159.6, 149.7, 148.1, 140.7, 139.9, 136.3, 135.1, 133.8, 127.3, 125.4, 124.7, 124.6, 123.5, 123.0, 121.7, 120.7, 120.0, 53.0, 24.8; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₂₀H₁₅NO₂S, 333.0823; found, 333.0824.



methyl 4-(9-ethyl-9*H*-carbazol-2-yl)-6-methylpicolinate (**32**): Following the general procedure A for pyridine synthesis with α , β -unsaturated oxime **17** (64 mg, 0.20 mmol) and methyl acrylate (**2a**), purification by flash column chromatography (hexane : AcOEt = 3 : 1) afforded the title compound (yellow oil, 38 mg, 55% yield). ¹H NMR (CDCl₃, 300 MHz) δ 8.44 (d, 1H, *J* = 1.5 Hz), 8.35 (d, 1H, *J* = 1.5 Hz), 8.18 (d, 1H, *J* = 7.8 Hz), 7.81 (dd, 1H, *J* = 8.7, 1.8 Hz), 7.70 (d, 1H, *J* = 1.5 Hz), 7.56–7.43 (m, 3H), 7.29 (td, 1H, *J* = 8.7, 1.5 Hz), 4.41 (q, 2H, *J* = 7.2 Hz), 4.06 (s, 3H), 2.75 (s, 3H), 1.47 (t, 3H, *J* = 7.2 Hz).¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 166.4, 159.3, 150.6, 147.9, 140.6, 140.5, 127.9, 126.3, 124.7, 124.3, 123.7, 122.9, 120.6, 119.5, 119.2, 109.0, 108.8, 53.0, 37.8, 24.8, 13.8; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₂₂H₂₀N₂O₂, 344.1525; found, 344.1520.



methyl 4-phenyl-6,7-dihydro-5*H*-cyclopenta[*b*]pyridine-2-carboxylate (**33**): Following the general procedure A for pyridine synthesis with α , β -unsaturated oxime **18** (46 mg, 0.20 mmol) and methyl acrylate (**2a**), purification by flash column chromatography (hexane : AcOEt = 1 : 1) afforded the title compound (white solid, 42 mg, 83% yield). ¹H NMR (CDCl₃, 300 MHz) δ 8.03 (s, 1H), 7.60–7.40 (m, 5H), 4.02 (s, 3H), 3.12 (t, 2H, *J* = 7.5 Hz), 3.10 (t, 2H, *J* = 7.5 Hz), 2.16 (tt, 2H, *J* = 7.5, 7.5 Hz). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 167.4, 166.3, 146.6, 145.9, 139.0, 137.8, 128.7, 128.2, 123.0, 52.8, 34.6, 31.1, 23.6; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₁₆H₁₅NO₂, 253.1103; found, 253.1104.



methyl 4-(4-methoxyphenyl)-6,7-dihydro-5*H*-cyclopenta[*b*]pyridine-2-carboxylate (**34**): Following the general procedure A for pyridine synthesis with α , β -unsaturated oxime **19** (52 mg, 0.20 mmol) and methyl acrylate (**2a**), purification by flash column chromatography (hexane : AcOEt = 1 : 1) afforded the title compound (white solid, 40 mg, 70% yield). ¹H NMR (CDCl₃, 300 MHz) δ 8.01 (s, 1H), 7.48 (d, 2H, *J* = 9.0 Hz), 7.01 (d, 2H, *J* = 9.0 Hz), 4.01 (s, 3H), 3.87 (s, 3H), 3.17 (t, 2H, *J* = 7.5 Hz), 3.10 (t, 2H, *J* = 7.5 Hz), 2.15 (tt, 2H, *J* = 7.5, 7.5 Hz). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 167.3, 166.4, 160.0, 146.5, 145.5, 138.5, 130.0, 129.5, 122.7, 114.1, 55.3, 52.8, 34.6, 31.3, 23.6; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₁₇H₁₇NO₃, 283.1208; found, 283.1210.



methyl 4-(4-chlorophenyl)-6,7-dihydro-5*H*-cyclopenta[*b*]pyridine-2-carboxylate (**35**): Following the general procedure A for pyridine synthesis with α , β -unsaturated oxime **20** (53 mg, 0.20 mmol) and methyl acrylate (**2a**), purification by flash column chromatography (hexane : AcOEt = 5 : 1) afforded

the title compound (white solid, 53 mg, 91% yield). ¹H NMR (CDCl₃, 300 MHz) δ 7.99 (s, 1H), 7.50– 7.40 (m, 4H), 4.02 (s, 3H), 3.18 (t, 2H, *J* = 7.8 Hz), 3.07 (t, 2H, *J* = 7.5 Hz), 2.17 (tt, 2H, *J* = 7.8, 7.5 Hz). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 167.5, 166.1, 146.7, 144.7, 138.8, 136.1, 134.9, 129.5, 129.0, 122.6, 52.8, 34.5, 31.0, 23.5; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₁₆H₁₄ClNO₂, 287.0713, 289.0684; found, 287.0721, 289.0690.



ethyl (*E*)-6-(4-methylstyryl)-4-(*p*-tolyl)picolinate (**42**): Following the general procedure A for pyridine synthesis with $\alpha_{,\beta}$ -unsaturated oxime **6** (32 mg, 0.10 mmol) and ethyl acrylate (**2b**), purification by flash column chromatography (hexane : AcOEt = 5 : 1) afforded the title compound (pale yellow oil, 31 mg, 86% yield). ¹H NMR (CDCl₃, 300 MHz) δ 8.18 (d, 1H, *J* = 1.5 Hz), 7.81 (d, 1H, *J* = 1.5 Hz), 7.67 (d, 1H, *J* = 15.6 Hz), 7.63 (d, 2H, *J* = 7.8 Hz), 7.52 (d, 2H, *J* = 8.1 Hz), 7.35–7.27 (m, 3H), 7.20 (d, 2H, *J* = 8.1 Hz), 4.52 (q, 2H, *J* = 7.2 Hz), 2.44 (s, 3H), 2.38 (s, 3H), 1.48 (t, 3H, *J* = 7.2 Hz). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 165.6, 156.9, 149.8, 148.7, 139.6, 138.7, 134.6, 134.1, 129.9, 129.8, 129.5, 127.2, 127.1, 126.9, 121.6, 121.0, 62.0, 21.32, 21.27, 14.4; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₂₄H₂₃NO₂, 356.1729; found, 356.1718.



benzyl (*E*)-6-(4-methylstyryl)-4-(*p*-tolyl)picolinate (**43**): Following the general procedure B for pyridine synthesis with α , β -unsaturated oxime **6** (32 mg, 0.10 mmol) and benzyl acrylate (**2c**), purification by flash column chromatography (hexane : AcOEt = 5 : 1) afforded the title compound (pale yellow solid, 33 mg, 79% yield). ¹H NMR (CDCl₃, 300 MHz) δ 8.16 (d, 1H, *J* = 1.5 Hz), 7.79 (d, 1H, *J* = 1.5 Hz), 7.68 (d, 1H, *J* = 16.2 Hz), 7.61 (d, 2H, *J* = 8.1 Hz), 7.55–7.47 (m, 4H), 7.45–7.26 (m, 6H), 7.20 (d, 2H, *J* = 7.8 Hz), 5.50 (s, 2H), 2.43 (s, 3H), 2.38 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 165.4, 157.0, 149.9, 148.5, 139.6, 138.7, 135.8, 134.6, 134.2, 133.6, 129.9, 129.5, 128.6, 128.4, 128.3, 127.2, 126.9, 126.8, 121.8, 121.2, 67.4, 21.3, 21.2; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₂₉H₂₅NO₂, 419.1885; found, 419.1872.



2-methoxyethyl (*E*)-6-(4-methylstyryl)-4-(*p*-tolyl)picolinate (**44**): Following the general procedure B for pyridine synthesis with α , β -unsaturated oxime **6** (32 mg, 0.10 mmol) and 2-methoxyethyl acrylate (**2d**), purification by flash column chromatography (hexane : AcOEt = 4 : 1) afforded the title compound (pale yellow solid, 36 mg, 93% yield). ¹H NMR (CDCl₃, 300 MHz) δ 8.11 (d, 1H, *J* = 1.5 Hz), 7.72 (d, 1H, *J* = 1.5 Hz), 7.61 (d, 1H, *J* = 16.2 Hz), 7.55 (d, 2H, *J* = 8.1 Hz), 7.44 (d, 2H, *J* = 8.1 Hz), 7.26–7.21 (m, 3H), 7.13 (d, 2H, *J* = 8.1 Hz), 4.54 (t, 2H, *J* = 4.8 Hz), 3.74 (t, 2H, *J* = 4.8 Hz), 3.39 (s, 3H), 2.36 (s, 3H), 2.31 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 165.5, 157.0, 149.9, 148.3, 139.6, 138.7, 134.6, 134.1, 133.6, 129.9, 129.5, 127.2, 126.9, 126.8, 121.8, 121.2, 70.4, 64.7, 59.1, 21.3, 21.2; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₂₅H₂₅NO₃, 387.1834; found, 387.1826.



ethyl 6-methyl-4-(*p*-tolyl)picolinate (**45**): Following the general procedure A for pyridine synthesis with α , β -unsaturated oxime **12** (43 mg, 0.20 mmol) and ethyl acrylate (**2b**), purification by flash column chromatography (hexane : AcOEt = 5 : 1) afforded the title compound (white solid, 40 mg, 80% yield). ¹H NMR (CDCl₃, 300 MHz) δ 8.17 (d, 1H, *J* = 1.5 Hz), 7.58 (d, 2H, *J* = 8.1 Hz), 7.53 (d, 1H, *J* = 1.5 Hz), 7.30 (d, 2H, *J* = 8.1 Hz), 4.51 (q, 2H, *J* = 7.2 Hz), 2.71 (s, 3H), 2.42 (s, 3H), 1.45 (t, 3H, *J* = 7.2 Hz). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 165.6, 159.4, 149.5, 148.3, 139.5, 134.5, 129.8, 126.8, 124.0, 120.3, 61.9, 24.7, 21.2, 14.3; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₁₆H₁₇NO₂, 255.1259; found, 255.1268.



benzyl 6-methyl-4-(*p*-tolyl)picolinate (**46**): Following the general procedure B for pyridine synthesis with α ,β-unsaturated oxime **12** (43 mg, 0.20 mmol) and benzyl acrylate (**2c**), purification by flash column chromatography (hexane : AcOEt = 5 : 1) afforded the title compound (white solid, 43 mg, 70% yield). ¹H NMR (CDCl₃, 300 MHz) δ 8.15 (d, 1H, *J* = 1.2 Hz), 7.58–7.48 (m, 5H), 7.40–7.26

(m, 5H), 5.48 (s, 2H), 2.71 (s, 3H), 2.41 (s, 3H). ${}^{13}C{}^{1}H$ NMR (CDCl₃, 75 MHz) δ 165.4, 159.5, 149.6, 148.1, 139.6, 135.9, 134.5, 129.9, 128.5, 128.3, 126.9, 124.2, 120.5, 67.4, 24.7, 21.2; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₂₁H₁₉NO₂, 317.1416; found, 317.1420.



2-methoxyethyl 6-methyl-4-(*p*-tolyl)picolinate (**47**): Following the general procedure B for pyridine synthesis with α , β -unsaturated oxime **12** (43 mg, 0.20 mmol) and 2-methoxyethyl acrylate (**2d**), purification by flash column chromatography (hexane : AcOEt = 3 : 1) afforded the title compound (colorless oil, 38 mg, 66% yield). ¹H NMR (CDCl₃, 300 MHz) δ 8.09 (d, 1H, *J* = 1.5 Hz), 7.50 (d, 2H, *J* = 8.1 Hz), 7.45 (d, 1H, *J* = 1.5 Hz), 7.22 (d, 2H, *J* = 8.1 Hz), 4.51 (t, 2H, *J* = 4.8 Hz), 3.71 (t, 2H, *J* = 4.8 Hz), 3.36 (s, 3H), 2.63 (s, 3H), 2.34 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 165.5, 159.5, 149.6, 147.9, 139.5, 134.5, 129.8, 126.9, 124.3, 124.1, 120.5, 120.4, 70.3, 64.5, 59.0, 58.9, 24.7, 21.2; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₁₇H₁₉NO₃, 285.1365; found, 285.1368.



isopropyl 6-methyl-4-(*p*-tolyl)picolinate (**48**): Following the general procedure B for pyridine synthesis with α_{β} -unsaturated oxime **12** (43 mg, 0.20 mmol) and isopropyl acrylate (**2e**), purification by flash column chromatography (hexane : AcOEt = 3 : 1) afforded the title compound (white solid, 51 mg, 95% yield). ¹H NMR (CDCl₃, 300 MHz) δ 8.11 (d, 1H, *J* = 1.5 Hz), 7.57 (d, 2H, *J* = 7.8 Hz), 7.51 (d, 1H, *J* = 1.5 Hz), 7.30 (d, 2H, *J* = 7.8 Hz), 5.40–5.30 (m, 1H), 2.71 (s, 3H), 2.42 (s, 3H), 1.43 (d, 6H, *J* = 6.3 Hz). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 165.0, 159.4, 149.5, 148.6, 139.4, 134.6, 129.8, 126.9, 123.9, 120.1, 69.4, 24.7, 21.8, 21.2; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₁₇H₁₉NO₂, 269.1416; found, 269.1418.



cyclohexyl 6-methyl-4-(*p*-tolyl)picolinate (49): Following the general procedure B for pyridine synthesis with α , β -unsaturated oxime 12 (43 mg, 0.20 mmol) and cyclohexyl acrylate (2f),

purification by flash column chromatography (hexane : AcOEt = 4 : 1) afforded the title compound (colorless oil, 59 mg, 94% yield). ¹H NMR (CDCl₃, 300 MHz) δ 8.10 (d, 1H, *J* = 1.5 Hz), 7.57 (d, 2H, *J* = 8.1 Hz), 7.50 (d, 1H, *J* = 1.5 Hz), 7.30 (d, 2H, *J* = 8.1 Hz), 5.14–5.05 (m, 1H), 2.71 (s, 3H), 2.42 (s, 3H), 2.15–2.00 (m, 2H), 1.90–1.75 (m, 2H), 1.70–1.20 (m, 6H). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 164.8, 159.4, 149.4, 148.7, 139.4, 134.7, 129.8, 126.8, 123.9, 120.1, 74.2, 31.6, 25.4, 24.7, 23.9, 21.2; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₂₀H₂₃NO₂, 309.1729; found, 309.1732.



(3s,5s,7s)-adamantan-1-yl 6-methyl-4-(*p*-tolyl)picolinate (**50**): Following the general procedure B for pyridine synthesis with α , β -unsaturated oxime **12** (43 mg, 0.20 mmol) and adamantan-1-yl acrylate (**2g**), purification by flash column chromatography (hexane : AcOEt = 4 : 1) afforded the title compound (colorless oil, 60 mg, 83% yield). ¹H NMR (CDCl₃, 300 MHz) δ 8.04 (d, 1H, *J* = 1.5 Hz), 7.55 (d, 2H, *J* = 7.8 Hz), 7.48 (d, 1H, *J* = 1.5 Hz), 7.29 (d, 2H, *J* = 7.8 Hz), 2.69 (s, 3H), 2.42 (s, 3H), 2.35–2.30 (m, 6H), 2.25–2.20 (m, 3H), 1.80–1.60 (m, 6H). ¹³C {¹H} NMR (CDCl₃, 75 MHz) δ 164.0, 159.3, 149.5, 149.4, 139.3, 134.8, 129.8, 126.9, 123.6, 119.9, 82.1, 41.2, 36.2, 30.9, 24.7, 21.2; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₂₄H₂₇NO₂, 361.2042; found, 361.2037.



N,*N*,6-trimethyl-4-(*p*-tolyl)picolinamide (**52**): Following the general procedure B for pyridine synthesis with α , β -unsaturated oxime **12** (43 mg, 0.20 mmol) and *N*,*N*-dimethylacrylamide (**2i**), purification by flash column chromatography (AcOEt only) afforded the title compound (colorless oil, 22 mg, 43% yield). ¹H NMR (CDCl₃, 300 MHz) δ 7.60 (d, 1H, *J* = 1.5 Hz), 7.55 (d, 2H, *J* = 8.1 Hz), 7.39 (d, 1H, *J* = 1.5 Hz), 7.28 (d, 2H, *J* = 8.1 Hz), 3.15 (s, 3H), 3.08 (s, 3H), 2.63 (s, 3H), 2.41 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 169.5, 157.9, 154.5, 149.6, 139.4, 134.8, 129.8, 126.8, 121.4, 118.0, 39.0, 35.6, 24.5, 21.2; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₁₆H₁₈N₂O, 254.1419; found, 254.1418.



4-(4-chlorophenyl)-*N*,*N*,6-trimethylpicolinamide (**53**): Following the general procedure B for pyridine synthesis with α , β -unsaturated oxime **14** (24 mg, 0.10 mmol) and *N*,*N*-dimethylacrylamide (**2i**), purification by flash column chromatography (AcOEt only) afforded the title compound (colorless oil, 17 mg, 62% yield). ¹H NMR (CDCl₃, 300 MHz) δ 7.58 (d, 2H, *J* = 8.7 Hz), 7.57 (d, 1H, *J* = 1.2 Hz), 7.46 (d, 2H, *J* = 8.7 Hz), 7.37 (d, 1H, *J* = 1.2 Hz), 3.15 (s, 3H), 3.10 (s, 3H), 2.64 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 169.2, 158.1, 154.7, 148.5, 136.3, 135.5, 129.3, 128.3, 121.4, 118.2, 39.0, 35.7, 24.5; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₁₅H₁₅ClN₂O, 274.0873; found, 274.0869.



4-(4-methoxyphenyl)-*N*,*N*-dimethyl-6,7-dihydro-5*H*-cyclopenta[*b*]pyridine-2-carboxamide (54): Following the general procedure B for pyridine synthesis with α , β -unsaturated oxime 19 (26 mg, 0.10 mmol) and *N*,*N*-dimethylacrylamide (2i), purification by flash column chromatography (AcOEt only) afforded the title compound (colorless oil, 26 mg, 88% yield). ¹H NMR (CDCl₃, 300 MHz) δ 7.46 (d, 2H, *J* = 8.7 Hz), 7.41 (s, 1H), 6.99 (d, 2H, *J* = 8.7 Hz), 3.86 (s, 3H), 3.14 (s, 3H), 3.11 (s, 3H), 3.10–3.05 (m, 4H), 2.20–2.10 (m, 2H). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 169.7, 165.4, 159.9, 152.9, 145.7, 135.1, 130.4, 129.4, 120.0, 114.1, 55.3, 39.1, 35.6, 34.4, 31.1, 23.5; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₁₈H₂₀N₂O₂, 296.1525; found, 296.1523.



4-(4-chlorophenyl)-N,N-dimethyl-6,7-dihydro-5H-cyclopenta[b]pyridine-2-carboxamide (55): Following the general procedure B for pyridine synthesis with α , β -unsaturated oxime 20 (26 mg, 0.10 mmol) and *N*,*N*-dimethylacrylamide (**2i**), purification by flash column chromatography (hexane : AcOEt = 2 : 1) afforded the title compound (colorless oil, 28 mg, 94% yield). ¹H NMR (CDCl₃, 300 MHz) δ 7.44 (s, 4H), 7.41 (s, 1H), 3.14 (s, 3H), 3.11 (s, 3H), 3.11–3.00 (m, 4H), 2.19–2.13 (m, 2H). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 169.4, 165.7, 153.1, 144.9, 136.5, 135.4, 134.7, 129.4, 128.9, 120.2, 39.1, 35.7, 34.4, 30.8, 23.4; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₁₇H₁₇ClN₂O, 300.1029, 302.1000; found, 300.1017, 302.0986.



4-(4-methoxyphenyl)-*N*-phenyl-6,7-dihydro-5*H*-cyclopenta[*b*]pyridine-2-carboxamide (56): Following the general procedure B for pyridine synthesis with α , β -unsaturated oxime 19 (26 mg, 0.10 mmol) and *N*-phenyl acrylamide (2j), purification by flash column chromatography (hexane : AcOEt = 5 : 1) afforded the title compound (white solid, 20 mg, 58% yield). ¹H NMR (CDCl₃, 300 MHz) δ 8.15 (s, 1H), 7.81 (d, 2H, *J* = 8.4 Hz), 7.51 (d, 2H, *J* = 9.0 Hz), 7.39 (dd, 2H, *J* = 9.0, 7.5 Hz), 7.14 (t, 1H, *J* = 7.5 Hz), 7.01 (d, 2H, *J* = 9.0 Hz), 3.87 (s, 3H), 3.15–3.09 (m, 4H), 2.25–2.15 (m, 2H). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 165.5, 162.7, 160.0, 148.5, 146.1, 138.0, 137.8, 130.3, 129.6, 129.0, 124.0, 119.7, 119.6, 114.1, 55.4, 34.2, 31.3, 23.7; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₂₂H₂₀N₂O₂, 344.1525; found, 344.1513.



N-butyl-4-(4-methoxyphenyl)-6,7-dihydro-5*H*-cyclopenta[*b*]pyridine-2-carboxamide (57): Following the general procedure B for pyridine synthesis with α , β -unsaturated oxime **19** (26 mg, 0.10 mmol) and *N*-butyl acrylamide (**2k**), purification by flash column chromatography (hexane : AcOEt = 3 : 1) afforded the title compound (colorless oil, 27 mg, 84% yield). ¹H NMR (CDCl₃, 300 MHz) δ 8.15–8.05 (br, 1H), 8.05 (s, 1H), 7.49 (d, 2H, *J* = 9.0 Hz), 6.99 (d, 2H, *J* = 9.0 Hz), 3.87 (s, 3H), 3.48 (q, 2H, *J* = 7.2 Hz), 3.11–3.02 (m, 4H), 2.18–2.10 (m, 2H), 1.70–1.64 (m, 2H), 1.50–1.40 (m, 2H), 0.97 (t, 3H, *J* = 7.2 Hz). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 165.4, 164.9, 159.9, 148.8, 145.7, 137.1, 130.4, 129.6, 119.3, 114.0, 55.3, 39.1, 34.2, 31.8, 31.2, 23.7, 20.2, 13.8; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₂₀H₂₄N₂O₂, 324.1838; found, 324.1835.



(4-(4-methoxyphenyl)-6,7-dihydro-5*H*-cyclopenta[*b*]pyridin-2-yl)(morpholino)methanone (58): Following the general procedure B for pyridine synthesis with α_{β} -unsaturated oxime 19 (26 mg, 0.10 mmol) and 4-acryloylmorpholine (21), purification by flash column chromatography (AcOEt only) afforded the title compound (colorless oil, 30 mg, 90% yield). ¹H NMR (CDCl₃, 300 MHz) δ 7.46 (d, 2H, *J* = 8.7 Hz), 7.45 (s, 1H), 6.99 (d, 2H, *J* = 8.7 Hz), 3.86 (s, 3H), 3.85–3.75 (m, 4H), 3.75–3.60 (m, 4H), 3.15–3.04 (m, 4H), 2.20–2.09 (m, 2H). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 168.2, 165.6, 159.9, 152.0, 145.8, 135.5, 130.2, 129.4, 120.6, 114.1, 67.0, 66.8, 55.3, 47.9, 42.7, 34.5, 31.1, 23.5; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₂₀H₂₂N₂O₃, 338.1630; found, 338.1636.



N-methoxy-4-(4-methoxyphenyl)-*N*-methyl-6,7-dihydro-5*H*-cyclopenta[*b*]pyridine-2-carboxamide (**59**): Following the general procedure B for pyridine synthesis with α , β -unsaturated oxime **19** (26 mg, 0.10 mmol) and *N*-methoxy-*N*-methyl acrylamide (**2m**), purification by flash column chromatography (hexane : AcOEt = 3 : 1) afforded the title compound (white solid, 15 mg, 48% yield). ¹H NMR (CDCl₃, 300 MHz) δ 7.47 (s, 1H), 7.46 (d, 2H, *J* = 9.0 Hz), 6.99 (d, 2H, *J* = 9.0 Hz), 3.86 (s, 3H), 3.79 (s, 3H), 3.42 (s, 3H), 3.13–3.04 (m, 4H), 2.20–2.10 (m, 2H). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 165.7, 159.9, 151.4, 145.4, 135.9, 130.4, 129.5, 120.2, 114.1, 61.4, 55.3, 34.4, 31.1, 23.5; HRMS (ESI-TOF) *m/z*: [M+Na]⁺ Calcd for C₁₈H₂₀N₂NaO₃, 335.1372; found, 335.1370.



4-(4-methoxyphenyl)-2-phenyl-6,7-dihydro-5*H*-cyclopenta[*b*]pyridine (**60**): Following the general procedure A for pyridine synthesis with α , β -unsaturated oxime **19** (26 mg, 0.10 mmol) and styrene

(2n), purification by flash column chromatography (hexane : AcOEt = 10 : 1) afforded the title compound (white solid, 10 mg, 33% yield). ¹H NMR (CDCl₃, 300 MHz) δ 7.97 (d, 2H, *J* = 8.7 Hz), 7.53–7.40 (m, 6H), 7.02 (d, 2H, *J* = 8.7 Hz), 3.88 (s, 3H), 3.15 (t, 2H, *J* = 7.8 Hz), 3.07 (t, 2H, *J* = 7.2 Hz), 2.20–2.13 (m, 2H). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 166.6, 159.7, 156.4, 145.5, 140.0, 132.9, 131.3, 129.4, 128.6, 128.4, 127.0, 117.9, 114.1, 55.4, 34.8, 30.8, 23.6; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₂₁H₁₉NO, 301.1467; found, 301.1469.



4-(4-methoxyphenyl)-2-(4-nitrophenyl)-6,7-dihydro-5*H*-cyclopenta[*b*]pyridine (**61**): Following the general procedure A for pyridine synthesis with $\alpha_{,\beta}$ -unsaturated oxime **19** (26 mg, 0.10 mmol) and 4-nitrostyrene (**20**), purification by flash column chromatography (hexane : AcOEt = 4 : 1) afforded the title compound (pale yellow solid, 16 mg, 46% yield). ¹H NMR (CDCl₃, 300 MHz) δ 8.30 (d, 2H, *J* = 9.0 Hz), 8.18 (d, 2H, *J* = 9.0 Hz), 7.58 (s, 1H), 7.49 (d, 2H, *J* = 9.0 Hz), 7.03 (d, 2H, *J* = 9.0 Hz), 3.89 (s, 3H), 3.16 (t, 2H, *J* = 7.8 Hz), 3.10 (t, 2H, *J* = 7.8 Hz), 2.25–2.10 (m, 2H). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 167.3, 159.9, 153.6, 147.8, 146.1, 145.8, 134.6, 130.7, 129.4, 127.6, 123.9, 118.6, 114.2, 55.4, 34.7, 30.9, 23.5; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₂₁H₁₈N₂O₃, 346.1317; found, 346.1307.



methyl 4-(4-(4-methoxyphenyl)-6,7-dihydro-5*H*-cyclopenta[*b*]pyridin-2-yl)benzoate (62): Following the general procedure A for pyridine synthesis with α,β -unsaturated oxime 19 (26 mg, 0.10 mmol) and methyl 4-vinylbenzoate (2p), purification by flash column chromatography (hexane : AcOEt = 3 : 1) afforded the title compound (white solid, 20 mg, 56% yield). ¹H NMR (CDCl₃, 300 MHz) δ 8.13 (d, 2H, *J* = 8.7 Hz), 8.07 (d, 2H, *J* = 8.7 Hz), 7.56 (s, 1H), 7.49 (d, 2H, *J* = 9.0 Hz), 7.02 (d, 2H, *J* = 9.0 Hz), 3.94 (s, 3H), 3.88 (s, 3H), 3.16 (t, 2H, *J* = 7.5 Hz), 3.08 (t, 2H, *J* = 7.5 Hz), 2.20–2.13 (m, 2H). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 167.0, 166.9, 159.8, 155.1, 145.6, 144.3, 133.8, 131.1, 130.0, 129.8, 129.4, 126.8, 118.3, 114.1, 55.4, 52.1, 34.7, 30.9, 23.6; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₂₃H₂₁NO₃, 359.1521; found, 359.1522.



4-(4-methoxyphenyl)-2-(4-(trifluoromethyl)phenyl)-6,7-dihydro-5*H*-cyclopenta[*b*]pyridine (63): Following the general procedure A for pyridine synthesis with α , β -unsaturated oxime 19 (26 mg, 0.10 mmol) and 4-trifluoromethylstyrene (2q), purification by flash column chromatography (hexane : AcOEt = 4 : 1) afforded the title compound (white solid, 33 mg, 89% yield). ¹H NMR (CDCl₃, 300 MHz) δ 8.11 (d, 2H, *J* = 8.1 Hz), 7.71 (d, 2H, *J* = 8.1 Hz), 7.53 (s, 1H), 7.49 (d, 2H, *J* = 8.7 Hz), 7.02 (d, 2H, *J* = 8.7 Hz), 3.88 (s, 3H), 3.16 (t, 2H, *J* = 7.5 Hz), 3.09 (t, 2H, *J* = 7.5 Hz), 2.20–2.13 (m, 2H). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 167.0, 159.9, 154.7, 142.6 (q, *J* = 173 Hz), 133.9, 131.0, 129.4, 127.2, 125.6, 125.5, 118.2, 114.1, 55.4, 34.7, 30.9, 23.6; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₂₂H₁₈F₃NO, 369.1340; found, 369.1346.



4-(4-methoxyphenyl)-2-(perfluorophenyl)-6,7-dihydro-5*H*-cyclopenta[*b*]pyridine (64): Following the general procedure A for pyridine synthesis with α , β -unsaturated oxime 19 (26 mg, 0.10 mmol) and pentafluorostyrene (2r), purification by flash column chromatography (hexane : AcOEt = 10 : 1) afforded the title compound (pale yellow solid, 36 mg, 91% yield).

1.0 mmol scale synthesis: Following the general procedure A for pyridine synthesis with α , β -unsaturated oxime **19** (259 mg, 1.0 mmol) and pentafluorostyrene (**2r**), purification by flash column chromatography (hexane : AcOEt = 10 : 1) afforded the title compound (pale yellow solid, 290 mg, 74% yield). ¹H NMR (CDCl₃, 300 MHz) δ 7.46 (d, 2H, J = 8.7 Hz), 7.25 (s, 1H), 7.01 (d, 2H, J = 8.1 Hz), 3.87 (s, 3H), 3.20–3.09 (m, 4H), 2.21–2.15 (m, 2H). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 167.3, 160.0, 146.3 (m), 145.6, 144.6, 142.9 (m), 139.3 (m), 136.1 (m), 134.9, 130.2, 129.5, 122.7, 115.9

(m), 114.2, 55.4, 34.6, 31.0, 23.4; HRMS (EI-quadrupole) m/z: [M]⁺ Calcd for C₂₁H₁₄F₅NO, 391.0996; found, 391.1001.



4-(4-chlorophenyl)-2-(perfluorophenyl)-6,7-dihydro-5*H*-cyclopenta[*b*]pyridine (**65**): Following the general procedure A for pyridine synthesis with $\alpha_{,\beta}$ -unsaturated oxime **20** (26 mg, 0.10 mmol) and pentafluorostyrene (**2r**), purification by flash column chromatography (hexane : AcOEt = 4 : 1) afforded the title compound (pale yellow solid, 37 mg, 93% yield). ¹H NMR (CDCl₃, 300 MHz) δ 7.60–7.40 (m, 4H), 7.23 (s, 1H), 3.17 (t, 2H, *J* = 7.5 Hz), 3.09 (t, 2H, *J* = 7.5 Hz), 2.25–2.15 (m, 2H). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 167.6, 146.2 (m), 144.8, 143.0 (m), 139.2 (m), 136.4, 136.1 (m), 135.2, 134.9, 129.5, 129.0, 122.7, 115.6 (m), 34.6, 30.8, 23.3; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₂₀H₁₁ClF₅N, 395.0500; found, 395.0503.



dimethyl 4-(4-methoxyphenyl)-6,7-dihydro-5*H*-cyclopenta[*b*]pyridine-2,3-dicarboxylate (**66**): Following the general procedure B for pyridine synthesis with α_{β} -unsaturated oxime **19** (26 mg, 0.10 mmol) and dimethyl maleate (**2s**), purification by flash column chromatography (hexane : AcOEt = 1 : 1) afforded the title compound (colorless oil, 12 mg, 36% yield). ¹H NMR (CDCl₃, 300 MHz) δ 7.22 (d, 2H, *J* = 9.0 Hz), 6.95 (d, 2H, *J* = 9.0 Hz), 3.99 (s, 3H), 3.85 (s, 3H), 3.68 (s, 3H), 3.18 (t, 2H, *J* = 7.2 Hz), 2.86 (t, 2H, *J* = 7.5 Hz), 2.20–2.10 (m, 2H). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 168.3, 166.9, 165.6, 159.8, 144.5, 143.5, 140.1, 130.0, 129.5, 127.7, 113.9, 55.3, 53.2, 52.5, 34.7, 30.6, 23.0; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₁₉H₁₉NO₅, 341.1263; found, 341.1267.



8-(4-methoxyphenyl)-2-methyl-6,7-dihydrocyclopenta[*b*]pyrrolo[3,4-*e*]pyridine-1,3(2*H*,5*H*)-dione (67): Following the general procedure B for pyridine synthesis with α , β -unsaturated oxime 19 (52 mg, 0.20 mmol) and *N*-methylmaleimide (2t), purification by flash column chromatography (hexane : AcOEt = 2 : 1) afforded the title compound (white solid, 32 mg, 52% yield). ¹H NMR (CDCl₃, 300 MHz) δ 7.40 (d, 2H, *J* = 9.0 Hz), 7.20 (d, 2H, *J* = 9.0 Hz), 3.89 (s, 3H), 3.23 (t, 2H, *J* = 7.8 Hz), 3.17 (s, 3H), 2.99 (t, 2H, *J* = 7.5 Hz), 2.22–2.16 (m, 2H). ¹³C{¹H} NMR (CDCl₃, 75 MHz) δ 172.8, 166.8, 160.5, 151.8, 143.8, 141.1, 130.7, 124.7, 121.7, 113.6, 55.3, 34.8, 30.7, 23.8, 23.4; HRMS (EI-quadrupole) *m/z*: [M]⁺ Calcd for C₁₈H₁₆N₂O₃, 308.1161; found, 308.1169.

ωB97X-D/6-311+G(d,p) Calculated cartesian coordinates

6-membered α,β -unsaturated oxime **36**

Ν	-2.4498067	-0.5779425	-0.0008641
0	-3.8008942	-0.7415300	-0.3370266
С	-4.2518757	-2.0407414	0.0973405
Η	-3.4955222	-2.7731817	-0.2130472
С	-5.5571246	-2.2886869	-0.6480961
Η	-5.4010911	-2.2410819	-1.7292994
Η	-5.9554733	-3.2762538	-0.3964858
Η	-6.3056246	-1.5377674	-0.3747898
С	-4.4056279	-2.0797881	1.6151445
Η	-3.4540875	-1.8396837	2.0958579
Η	-5.1564826	-1.3528525	1.9433083
Η	-4.7202169	-3.0752194	1.9462681
С	-2.0322546	0.6266512	-0.2106002
С	-0.5797720	0.8678899	-0.0107465
С	-2.9241148	1.7612737	-0.6716958
С	-0.1773584	2.2697199	0.4099645
С	-2.5006173	3.1224356	-0.1008374
Η	-2.8764758	1.7992434	-1.7701767
Η	-3.9594358	1.5262409	-0.4176857
С	-1.0025319	3.3599836	-0.2946245
Η	0.8863489	2.4255132	0.2134671
Н	-0.3152784	2.3835162	1.4967019


Н	-3.0867055	3.9163782	-0.5776835
Η	-2.7375356	3.1591209	0.9712329
Η	-0.7133694	4.3435539	0.0933556
Η	-0.7660614	3.3605743	-1.3672823
С	0.2904112	-0.1435593	-0.2506952
Η	-0.1450503	-1.0527308	-0.6592065
С	1.7445609	-0.1959332	-0.0640935
С	2.5018049	-1.0239655	-0.9108239
С	2.4451153	0.4911981	0.9510959
С	3.8861417	-1.1381313	-0.7980756
Η	1.9912341	-1.5879004	-1.6871175
С	3.8218791	0.3836221	1.0818100
Η	1.8989889	1.0892371	1.6715227
С	4.5573574	-0.4238947	0.2020495
Η	4.4246856	-1.7826670	-1.4825526
Η	4.3535420	0.9064679	1.8701189
0	5.9052781	-0.4573844	0.4118649
С	6.6974117	-1.2693556	-0.4406987
Η	7.7270839	-1.1469469	-0.1017890
Η	6.4173190	-2.3280038	-0.3675615
Н	6.6223518	-0.9509514	-1.4883176

7-membered α , β -unsaturated oxime **37**

Ν	2.3180980	-0.6950266	0.2827514
0	3.6573869	-0.9720668	-0.0474627
С	4.0784800	-2.1803356	0.6171177
Η	3.7566614	-2.1134710	1.6643107
С	5.5999894	-2.1784512	0.5382660
Η	6.0115116	-1.2808950	1.0081680
Н	6.0074457	-3.0565900	1.0483444
Н	5.9315246	-2.2037743	-0.5049554
С	3.4430739	-3.4057716	-0.0339437
Η	2.3537214	-3.3302356	0.0048682
Н	3.7513325	-3.4857539	-1.0819891
Η	3.7455280	-4.3207287	0.4865670
С	1.8794075	0.3532370	-0.3258586



S37

С	0.4574224	0.7168363	-0.0691687
С	2.6937565	1.1949065	-1.2828829
С	0.1394390	2.1335726	0.3873053
С	3.4194942	2.3722285	-0.5994091
Н	2.0152239	1.5804409	-2.0507324
Η	3.4241954	0.5528500	-1.7803426
С	1.0593088	3.2931923	-0.0560671
Η	0.1426440	2.1369396	1.4888021
Н	-0.8865052	2.3755640	0.0909209
С	2.5300527	3.1575088	0.3840731
Η	3.7863246	3.0435486	-1.3858378
Η	4.3011878	1.9935539	-0.0721461
Η	0.9980273	3.4400095	-1.1419141
Η	0.6377471	4.2024372	0.3883442
Η	2.9645109	4.1531119	0.5318977
Η	2.5540478	2.6706605	1.3678997
С	-0.4730123	-0.2512767	-0.2425450
Η	-0.0969833	-1.2022522	-0.6139276
С	-1.9297208	-0.2221892	-0.0509590
С	-2.7210646	-1.0753915	-0.8396694
С	-2.6027705	0.5674031	0.9061158
С	-4.1091542	-1.1224243	-0.7268334
Η	-2.2340114	-1.7159440	-1.5704086
С	-3.9837165	0.5275605	1.0368468
Η	-2.0370512	1.1956461	1.5832518
С	-4.7514980	-0.3096350	0.2152677
Η	-4.6729485	-1.7914775	-1.3659418
Η	-4.4937886	1.1303356	1.7811329
0	-6.1003613	-0.2698463	0.4194087
С	-6.9245567	-1.1073139	-0.3760387
Η	-6.6904188	-2.1688128	-0.2244587
Η	-7.9488732	-0.9167552	-0.0526824
Η	-6.8335291	-0.8698565	-1.4437008

Crystallographic description of 2-benzylidenecyclopentenone oxime ether (18)

CCDC-2166741 for 2-benzylidenecyclopentenone oxime ether (**18**) contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via <u>www.ccdc.cam.ac.uk/data_request/cif</u>.



Figure S1. ORTEP view of oxime 18.

References

- 1) T. Yamada, Y. Hashimoto, K. Tanaka. III, N. Morita, O. Tamura, Org. Lett. 2021, 23, 1659–1663.
- M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, G. A. Petersson, H. Nakatsuji, X. Li, M. Caricato, A. Marenich, J. Bloino, B. G. Janesko, R. Gomperts, B. Mennucci, H. P. Hratchian, J. V. Ortiz, A. F. Izmaylov, J. L. Sonnenberg, D. Williams-Young, F. Ding, F. Lipparini, F. Egidi, J. Goings, B. Peng, A. Petrone, T. Henderson, D. Ranasinghe, V. G. Zakrzewski, J. Gao, N. Rega, G. Zheng, W. Liang, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, K. Throssell, J. A. Montgomery, Jr., J. E. Peralta, F. Ogliaro, M. Bearpark, J. J. Heyd, E. Brothers, K. N. Kudin, V. N. Staroverov, T. Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, J. M. Millam, M. Klene, C. Adamo, R. Cammi, J. W. Ochterski, R. L. Martin, K. Morokuma, O. Farkas, J. B. Foresman, and D. J. Fox, Gaussian 09 Revision D.01; Gaussian, Inc.; Wallingford CT, 2013.
- a) J. M. Neely, T. Rovis, J. Am. Chem. Soc. 2013, 135, 66–69. b) S. Tang, J. He, Y. Sun, L. He, X. She. Org. Lett. 2009, 11, 3982–3985.

¹H-NMR of **L8** (300 MHz, CDCl₃)



¹³C-NMR of **L8** (75 MHz, CDCl₃)



¹H-NMR of **1f** (300 MHz, CDCl₃)



¹³C-NMR of **1f** (75 MHz, CDCl₃)



¹H-NMR of **1g** (300 MHz, CDCl₃)



¹³C-NMR of **1g** (75 MHz, CDCl₃)





S46

¹³C-NMR of **1h** (75 MHz, CDCl₃)





¹³C-NMR of **1i** (75 MHz, CDCl₃)



¹ H-NMR	of 1j ((300 MHz,	CDCl ₃)
--------------------	----------------	-----------	---------------------



¹³C-NMR of **1j** (75 MHz, CDCl₃)



¹H-NMR of **1k** (300 MHz, CDCl₃)



¹³C-NMR of **1k** (75 MHz, CDCl₃)

$\int_{\Gamma} 155.277$ 147.644 147.540 1144.124 139.092	136.325 136.016 135.511 128.957 128.957	128.720 128.595 127.352 127.188	L126.887 L126.887 L121.825 L117.083	L 111.062 77.424 77.001 76.578					Current NAME EXPNO PROCNO	Data Paran Yakka_Yan	neters nada_2 4481 1	
	F								F2 - Acq Date_ Time INSTRUM PROBHD PULPROG TD SOLVENT NS DS SWH FIDRES AQ RG DW DE TE D1 D11 TD0	180: 0.: 2.00 5 mm PABI 2: 1.80 0.: 1.81 2.00 0.03	210320 5.48 spect 30 BB- 29pg30 65536 CDC13 8000 4 28.846 275098 175317 2050 27.733 6.50 295.5 200000 1	Hz Hz sec usec usec k sec sec
				dephenormality of the planets		nterf o wild geta to be get	n ff attil gan pickt sign franklinne	nga bilanga talah sa kutur balangan angan	====== SF01 NUC1 P1 PLW1 ======= SF02 NUC2 CPDPRG[2 PCPD2 PLW12 PLW12 PLW12 PLW13 F2 - Pro SI SF WDW SSB LB GB PC	CHANNEL : 75.4 34.500 CHANNEL : 300.1: 0.21 0.13 0cessing p 75.4 0 0	1 ==== 22953 I 13C 10.00 V 200000 V 22 ==== 312005 I 1H altz16 80.00 V 99981 V 99981 V 99981 V 99981 V 99981 V 32768 577509 J EM 1.00	==== MHz μsec MHz usec W W W W Ts MHz Hz
180 160	140	120	100	80	60	40	20	ppm	10		1.10	

¹H-NMR of **1I** (300 MHz, CDCl₃)



¹³C-NMR of **1I** (75 MHz, CDCl₃)



¹H-NMR of **1m** (300 MHz, CDCl₃)



¹³C-NMR of **1m** (75 MHz, CDCl₃)



¹H-NMR of **1n** (300 MHz, CDCl₃)



¹³C-NMR of **1n** (75 MHz, CDCl₃)



¹H-NMR of **1o** (300 MHz, CDCl₃)







¹H-NMR of **36** (300 MHz, CDCl₃)



¹³C-NMR of **36** (75 MHz, CDCl₃)



¹H-NMR of **37** (300 MHz, CDCl₃)



¹³C-NMR of **37** (75 MHz, CDCl₃)



¹H-NMR of **38** (300 MHz, CDCl₃)



¹³C-NMR of **38** (75 MHz, CDCl₃)



¹H-NMR of **39** (300 MHz, CDCl₃)



¹³C-NMR of **39** (75 MHz, CDCl₃)



¹H-NMR of **40** (300 MHz, CDCl₃)



¹³C-NMR of **40** (75 MHz, CDCl₃)



¹H-NMR of **41** (300 MHz, CDCl₃)


¹³C-NMR of **41** (75 MHz, CDCl₃)



¹H-NMR of **74** (300 MHz, CDCl₃)



¹³C-NMR of **74** (75 MHz, CDCl₃)





S76

10.11.12



¹H-NMR of **78** (300 MHz, CDCl₃)



¹³C-NMR of **78** (75 MHz, CDCl₃)



¹H-¹H COSY spectrum of **78**







HMBC spectrum of 78





¹³C-NMR of (*E*)-**11** (75 MHz, CDCl₃)





¹³C-NMR of (*Z*)-**11** (75 MHz, CDCl₃)

